<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        92-116-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZARZIO 30 mU/0.5 mL solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        455.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="IDT Biologika GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            IDT Biologika GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zarzio is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of proteins called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Zarzio works by encouraging the bone marrow to produce more white blood cells.</p><p>&nbsp;</p><p>A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Zarzio stimulates the bone marrow to produce new white cells quickly.</p><p>&nbsp;</p><p><u>Zarzio can be used:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells after treatment with chemotherapy to help prevent infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells after a bone marrow transplant to help prevent infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; before high-dose chemotherapy to make the bone marrow produce more stem cells which can be collected and given back to you after your treatment. These can be taken from you or from a donor. The stem cells will then go back into the bone marrow and produce blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells if you suffer from severe chronic neutropenia to help prevent infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with advanced HIV infection which will help reduce the risk of infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp; <strong>&nbsp;Do not use Zarzio</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to filgrastim or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Zarzio.</p><p>Take special care with Zarzio if you have ever had an allergic reaction to latex. Please tell your doctor before starting treatment <strong>if you have</strong>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoporosis (bonedisease);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sickle cell anaemia, as Zarzio may cause sickle cell crisis.</p><p>&nbsp;</p><p>Please tell your doctor immediately during treatment with Zarzio, if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder [these may be symptoms of an enlarged spleen (splenomegaly), or possibly rupture of the spleen].</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; notice unusual bleeding or bruising [these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot].</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing as these could be signs of a severe allergic reaction (hypersensitivity).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual (glomerulonephritis).</p><p>&nbsp;</p><p>Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience thesesymptoms.</p><p>&nbsp;</p><p><strong>Loss of response to filgrastim</strong></p><p><strong>&nbsp;</strong></p><p>If you experience a loss of response or failure to maintain a response with filgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise filgrastim&rsquo;s activity.</p><p>&nbsp;</p><p>Your doctor may want to monitor you closely, see section 4 of the package leaflet.</p><p>&nbsp;</p><p>If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome [MDS]). You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop cancers of the blood, you should not use Zarzio unless instructed by your doctor.</p><p>&nbsp;</p><p>If you are a stem cell donor, you must be aged between 16 and 60 years.</p><p>&nbsp;</p><p><strong>Take special care with other products that stimulate white blood cells.</strong></p><p>Zarzio is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.</p><p>&nbsp;</p><p><strong>Other medicines and Zarzio</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Zarzio has not been tested in pregnant or breast-feeding women. Zarzio is not recommended during pregnancy.</p><p>&nbsp;</p><p>It is important to tell your doctor if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant orbreast-feeding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; think you may be pregnant; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are planning to have ababy.</p><p>&nbsp;</p><p>If you become pregnant during Zarzio treatment, please inform your doctor.</p><p>Unless your doctor directs you otherwise, you must stop breast feeding if you use Zarzio.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Zarzio may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after taking Zarzio and before driving or operating machinery.</p><p>&nbsp;</p><p><strong>Zarzio contains sorbitol</strong></p><p><strong>&nbsp;</strong></p><p>Zarzio contains sorbitol (E420).</p><p>&nbsp;</p><p>Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How is Zarzio given and how much should I take?</strong></p><p><strong>&nbsp;</strong></p><p>Zarzio is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). It can also be given as a daily slow injection into the vein (known as an intravenous infusion). The usual dose varies depending on your illness and weight. Your doctor will tell you how much Zarzio you should take.</p><p>&nbsp;</p><p>Patients having a bone marrow transplant after chemotherapy:</p><p>You will normally receive your first dose of Zarzio at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant.</p><p>&nbsp;</p><p>You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue your treatment at home. However, you should not attempt this unless you have been properly trained first by your health care provider.</p><p>&nbsp;</p><p><strong>How long will I have to take Zarzio?</strong></p><p><strong>&nbsp;</strong></p><p>You will need to take Zarzio until your white blood cell count is normal. Regular blood tests will be taken to monitor the number of white blood cells in your body. Your doctor will tell you how long you will need to take Zarzio.</p><p>&nbsp;</p><p><u>Use in children</u></p><p>&nbsp;</p><p>Zarzio is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia). The dosing in children receiving chemotherapy is the same as for adults.</p><p>&nbsp;</p><p><strong>If you use more Zarzio than you should</strong></p><p><strong>&nbsp;</strong></p><p>Do not increase the dose your doctor has given you. If you think you have injected more than you should, contact your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>If you forget to use Zarzio</strong></p><p><strong>&nbsp;</strong></p><p>If you have missed an injection, or injected too little, contact your doctor as soon as possible. Do not take a double dose to make up for any missed doses.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Please tell your doctor immediately </strong>during treatment<strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face lips, mouth, tongue or throat (angioedema) and shortness of breath (dyspnoea).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a cough, fever and difficulty breathing (dyspnoea) as this can be a sign of Acute Respiratory Distress Syndrome (ARDS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen [enlargement of the spleen (splenomegaly) or rupture of the spleen].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria). Your doctor may regularly test your urine if you experience this side effect or if protein is found in your urine (proteinuria).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any of the following or combination of the following side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.</p><p>These could be symptoms of a condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a combination of any of the following symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, or shivering, or feeling very cold, high heart rate, confusion or disorientation, shortness of breath, extreme pain or discomfort and clammy or sweaty skin.</p><p>These could be symptoms of a condition called &ldquo;sepsis&rdquo; (also called &quot;blood poisoning&quot;), a severe infection with whole-body inflammatory response which can be life threatening and needs urgent medical attention.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience kidney injury (glomerulonephritis). Kidney injury has been seen in patients who received filgrastim. Call your doctor right away if you experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.</p><p>&nbsp;</p><p>A common side effect of filgrastim use is pain in your muscles or bones (musculoskeletal pain), which can be helped by taking standard pain relief medicines (analgesics). In patients undergoing a stem cell or bone marrow transplant, Graft versus Host Disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints. Very commonly seen in normal stem cell donors is increase in white blood cells (leukocytosis) and decrease of platelets which reduces the ability of blood to clot (thrombocytopenia), these will be monitored by your doctor.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of platelets which reduces the ability of blood to clot (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell count (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair loss or thinning (alopecia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; soreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosalinflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lung (bronchitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased feeling of sensitivity, especially in the skin (hypoaesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness of the hands or feet (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood (haemoptysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your mouth and throat (oropharyngeal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds(epistaxis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlargement of the liver (hepatomegaly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin (erythema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; musclespasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine (dysuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generalised weakness (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the hands and feet (oedema peripheral)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of certain enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood chemistry</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transfusion reaction</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in white blood cells (leukocytosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (hypersensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rejection of transplanted bone marrow (graft versus host disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high uric acid levels in the blood, which may cause gout (hyperuricaemia) (Blood uric acid increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lungs do not function as they should, causing breathlessness (respiratory failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling and/or fluid in the lungs (pulmonary oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs (interstitial lung disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal x-rays of the lungs (lung infiltration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the lung (pulmonary haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of absorption of oxygen in the lung (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bumpy skin rash (rash macuo-papular)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease which causes bones to become less dense, making them weaker, more brittle and likely to break(osteoporosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden life-threatening allergic reaction (anaphylactic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain and swelling of the joints, similar to gout (pseudogout)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in how your body regulates fluids within your body and may result in puffiness (fluid volumedisturbances)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels in the skin (cutaneous vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever (Sweetssyndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of rheumatoidarthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual change in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone densitydecreased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the aorta (the large blood vessel which transports blood from the heart to the body), see section 2.</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the syringe label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light. Accidental freezing will not harm Zarzio.</p><p>&nbsp;</p><p>The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 72 hours (but not above 25&deg;C). At the end of this period, the product should not be put back in the refrigerator and should be disposed of.</p><p>&nbsp;</p><p>Do not use this medicine if you notice discolouration, cloudiness or particles, it should be a clear, colourless to slightly yellowish liquid.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is filgrastim.</p><p>Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 30 MU filgrastim in 0.5 ml, corresponding to 60 MU/ml.</p><p>Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 48 MU filgrastim in 0.5 ml, corresponding to 96 MU/ml</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glutamic acid, sorbitol (E420), polysorbate 80 and water for injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The needle cap of the syringe may contain dry rubber (latex).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zarzio is a clear, colourless to slightly yellowish solution for injection or infusion in pre-filled syringe.

Zarzio is available in packs containing 1, 3, 5 or 10 pre-filled syringes with injection needle and with or without a needle safety guard.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH Biochemiestr.10 6250 Kundl Austria</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p><strong>&nbsp;</strong>Sandoz GmbH Biochemiestr. 10</p><p>6336 Langkampfen Austria</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>عقار&nbsp;زارزيو&nbsp;هو أحد عوامل نمو خلايا الدَّم البيضاء (عامل تحفيز مستعمرات الخلايا المحببة) وينتمي&nbsp;إلى مجموعة من البروتينات&nbsp;تُسمى السِّيتوكينات. عوامل النمو هي البروتينات التي&nbsp;تُنتَج&nbsp;بشكل طبيعي في الجسم ولكن يُمكِن صناعتها أيضًا بالاستعانة بالتقنية الحيوية لاستخدامها كدواء. يعمل عقار&nbsp;زارزيو&nbsp;عن&nbsp;طريق&nbsp;حث النخاع العظمي على&nbsp;إنتاج&nbsp;المزيد من خلايا الدَّم البيضاء.&nbsp;</p><p>يُمكِن أن يحدث انخفاض في عدد خلايا الدَّم البيضاء (قلة خلايا العَدِلات) لأسباب&nbsp;كثيرة&nbsp;وينتج&nbsp;منه&nbsp;انخفاض&nbsp;قدرة جسمك على مكافحة العدوى. يحفز عقار&nbsp;زارزيو&nbsp;النخاع العظمي لإنتاج خلايا بيضاء جديدة&nbsp;سريعًا.&nbsp;</p><p>يُمكِن&nbsp;استخدام عقار&nbsp;زارزيو&nbsp;للأسباب التَّالية:&nbsp;</p><ul><li><p>لزيادة عدد خلايا الدَّم البيضاء بعد العلاج الكيميائي؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li></ul><ul><li><p>لزيادة عدد خلايا الدَّم البيضاء بعد عملية زرع النخاع العظمي؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li><li><p>قبل تلقي جرعات مرتفعة من العلاج الكيميائي لجعل النخاع العظمي ينتج المزيد من الخلايا الجذعية التي يُمكِن جمعها وإعادتها إليك بعد علاجك. يُمكِن أخذ هذه الخلايا الجذعية منك أو من أحد المتبرعين. ستعود الخلايا الجذعية بعد ذلك إلى النخاع العظمي وتنتج خلايا الدَّم.&nbsp;</p></li><li><p>لزيادة عدد خلايا الدَّم&nbsp;البيضاء&nbsp;إذا كنت&nbsp;تُعاني حالة مُزمِنة وشديدة من قلة خلايا العَدِلات؛ للمساعدة&nbsp;في&nbsp;الوقاية من العدوى.&nbsp;</p></li><li><p>لدى&nbsp;المرضى المُصابين بحالة متقدمة من&nbsp;عدوى&nbsp;فيروس&nbsp;نقص المناعة&nbsp;البشري سيُساعد العقار في تقليل خطر الإصابة بعدوى.&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم&nbsp;عقار&nbsp;زارزيو&nbsp;في الحالات التَّالية:</strong>&nbsp;</p><ul><li><p>إذا كنت تعاني حساسية&nbsp;تجاه&nbsp;فيلجراستيم&nbsp;أو&nbsp;أيٍّ&nbsp;من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم: 6).&nbsp;</p></li></ul><p><strong>تحذيرات واحتياطات&nbsp;</strong></p><p>تحدَّث إلى طبيبك أو الصيدلي الخاص بك أو الممرض(ة) قبل استخدام عقار&nbsp;زارزيو.&nbsp;</p><p>توخ حذرًا خاصًّا مع العلاج بعقار&nbsp;زارزيو&nbsp;إذا كنت قد تعرَّضت من قبل لأحد تفاعلات الحساسية&nbsp;تجاه مادة&nbsp;اللاتكس.&nbsp;</p><p>يُرجى إخبار طبيبك قبل بدء العلاج&nbsp;إذا كنت مصابًا بما يلي:&nbsp;</p><ul><li><p>هشاشة&nbsp;العظام (مرض&nbsp;يصيب العظام)؛&nbsp;</p></li><li><p>أنيميا الخلايا المنجلية؛ إذ قد يُؤدي عقار&nbsp;زارزيو&nbsp;إلى حدوث أزمة الخلايا المنجلية.&nbsp;</p></li></ul><p>أثناء العلاج بعقار&nbsp;زارزيو، يُرجى إخبار طبيبك فورًا إذا حدث أيٌّ&nbsp;مما يلي:&nbsp;</p><ul><li><p>أُصِبت بألم في الجزء العلوي الأيسر من البطن أو بألم أسفل الجهة اليسرى من القفص&nbsp;الصَّدري&nbsp;أو على طرف&nbsp;كتفك الأيسر [قد تكون هذه&nbsp;أعراض تضخُّم الطحال، أو ربما حدوث تمزُّق في الطحال].&nbsp;</p></li><li><p>لاحظت حدوث نزيف أو تكدُّم غير مُعتاد [قد تكون هذه أعراض انخفاض عدد الصفائح الدَّموية (نقحن الصفائح&nbsp;الدَّموية)، مع انخفاض قدرة الدَّم لديك على التجلُّط].&nbsp;</p></li><li><p>ظهرت لديك علامات حساسية مفاجئة مثل: الطفح الجلدي&nbsp;أو الحكة أو الشرى على الجلد، تورُّم الوجه أو الشفتين&nbsp;أو اللسان أو أجزاء أخرى من الجسم، ضيق بالتَّنفس، أزيز بالصدر أو مشاكل في التنفس؛ إذ قد تكون هذه علامات على الإصابة بتفاعل حساسية شديد (فرط حساسية).&nbsp;</p></li><li><p>تعرَّضت لانتفاخ بالوجه أو الكاحلين، وجود&nbsp;دم لديك في البول أو بول بني اللون أو لاحظت أنك تتبول بمعدل أقل&nbsp;من المُعتاد (التهاب&nbsp;كبيبات&nbsp;الكُلى).&nbsp;</p></li></ul><p>تم الإبلاغ عن حدوث التهاب في الشريان الأورطي (الوعاء الدَّموي الكبير الذي ينقل الدَّم من القلب الى الجسم) بصورة نادرة في مرضى السرطان والمتبرعين الأصحاء. قد تتضمن الأعراض&nbsp;حُمّى&nbsp;وألمًا بالبطن وشعورًا بالتَوَعُّك&nbsp;وألمًا بالظهر وزيادة الدلالات الالتهابية. أخبر طبيبك إذا كنت تعاني هذه الأعراض.&nbsp;</p><p><strong>فقدان الاستجابة&nbsp;للفيلجراستيم&nbsp;</strong></p><p>إذا تعرَّضت لفقدان الاستجابة أو الفشل في الحفاظ على الاستجابة مع العلاج&nbsp;بفيلجراستيم، سيبحث طبيبك أسباب ذلك ويشمل ذلك ما إذا كان جسمك قد أنتج أجسامًا مضادة&nbsp;تُبطِل&nbsp;نشاط&nbsp;فيلجراستيم&nbsp;أم لا.&nbsp;</p><p>قد يرغب طبيبك في مراقبتك عن كثب، انظر قسم: 4 في نشرة العبوة.&nbsp;</p><p>إذا كنت&nbsp;مريضًا&nbsp;مُصابًا بحالة مُزمِنة وشديدة من قلة خلايا العَدِلات، فقد تكون&nbsp;مُعرَّضًا&nbsp;لخطر الإصابة بسرطان الدَّم (اللوكيميا، متلازمة خلل التَّنسج النخاعي). يجب عليك التحدُّث إلى طبيبك بشأن مخاطر إصابتك بمرض سرطان الدَّم وما هي الاختبارات التي يجب إجراؤها. إذا&nbsp;أُصِبت أو كان من المُحتَمَل&nbsp;أن تُصاب&nbsp;بسرطانات الدَّم، فيجب أَلَّا تستخدم عقار&nbsp;زارزيو&nbsp;ما لم يوجهك طبيبك باستخدامه.&nbsp;</p><p>إذا كنت مُتبرعًا بخلايا جذعية، فيجب أن يتراوح عُمْرك بين 16 و60 عامًا.&nbsp;</p><p><strong>توخ حذرًا خاصًا مع&nbsp;المُنتَجات&nbsp;الأخرى التي تحفز خلايا الدَّم البيضاء</strong>.&nbsp;</p><p>عقار&nbsp;زارزيو&nbsp;هو واحد من مجموعة من&nbsp;المُنتَجات&nbsp;التي تحفز إنتاج خلايا الدَّم&nbsp;البيضاء. يجب دائمًا على&nbsp;اختصاصي&nbsp;الرعاية&nbsp;الصحية&nbsp;المتابع لك تسجيل المُنتَج&nbsp;الصحيح&nbsp;الذي تستخدمه.&nbsp;</p><p><strong>تناول&nbsp;أدوية أخرى مع عقار&nbsp;زارزيو&nbsp;</strong></p><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAYAAAANCAYAAACKCx+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAABXSURBVChTYyAbFAPxfyB+A8SGIAEQADFSIEwGHyBeCGEyMEgAMQ+ECRYEScIBiAMy6i4QS4IE0AHIrj1ADDMBDkACs4AYQxfIIb0QJsKpIIzVGIoAAwMAFpMNVX5o1QwAAAAASUVORK5CYIIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول&nbsp;أو تناولت&nbsp;مؤخرًا&nbsp;أو قد تتناول&nbsp;أيَّ&nbsp;أدوية&nbsp;أخرى.&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية&nbsp;</strong></p><p>لم يتم اختبار عقار&nbsp;زارزيو&nbsp;لدى&nbsp;السيدات الحوامل أو المُرضِعات.&nbsp;</p><p>لا يُنصح بتناول&nbsp;زارزيو&nbsp;أثناء الحمل.&nbsp;</p><p>&nbsp;</p><p>من المهم أن تخبري طبيبكِ&nbsp;في الحالات الآتية:&nbsp;</p><ul><li><p>إذا كنتِ&nbsp;حاملاً&nbsp;أو&nbsp;مرضعًا؛&nbsp;</p></li><li><p>إذا كنتِ&nbsp;تعتقدين&nbsp;بآنكِ&nbsp;قد تكونين حاملاً، أو&nbsp;</p></li><li><p>إذا كنتِ&nbsp;تخططين للحَمْل.&nbsp;</p></li></ul><p>إذا أصبحتِ&nbsp;حاملاً&nbsp;أثناء العلاج بعقار&nbsp;زارزيو، فيُرجى إبلاغ طبيبكِ.&nbsp;</p><p>يجب عليكِ&nbsp;التَّوقف عن ممارسة الرضاعة الطبيعية إذا كنتِ&nbsp;تستخدمين عقار&nbsp;زارزيو، ما لم يوجهكِ&nbsp;طبيبكِ&nbsp;بخلاف ذلك.&nbsp;</p><p><strong>القيادة واستخدام الآلات&nbsp;</strong></p><p>قد يكون لعقار&nbsp;زارزيو&nbsp;تأثير طفيف على قدرتك على قيادة المركبات واستخدام الآلات. قد يُسبب هذا الدَّواء دوخة. من المستحسن الانتظار ورؤية ما تشعر به بعد تلقي عقار&nbsp;زارزيو&nbsp;وقبل قيادة المركبات أو تشغيل الآلات.&nbsp;</p><p>عقار&nbsp;زارزيو&nbsp;يحتوي على&nbsp;السوربيتول&nbsp;</p><p>يحتوي عقار&nbsp;زارزيو&nbsp;على&nbsp;السوربيتول&nbsp;(E420).&nbsp;</p><p>السوربيتول&nbsp;هو أحد مصادر الفركتوز. إذا كان لديك (أو لدى طفلك) حالة وراثية من عدم تحمُّل الفركتوز، وهو اضطراب وراثي نادر، فيجب عليك (أو على طفلك) عدم تلقي هذا الدَّواء. المرضى ممن لديهم حالة وراثية&nbsp;من عدم تحمُّل&nbsp;الفركتوز لا تستطيع أجسامهم تكسير الفركتوز، مما قد يسبب آثارًا جانبية خطيرة.&nbsp;</p><p>يجب عليك إخبار طبيبك قبل تلقي هذا الدَّواء إذا كان لديك (أو&nbsp;لدى طفلك) حالة وراثية من عدم تحمُّل&nbsp;الفركتوز أو إذا لم يعد طفلك يستطيع تناوُل الأطعمة أو المشروبات المُحلاة بسبب شعوره بالإعياء أو&nbsp;رغبته في القيء أو تعرُّضه لآثار مزعجة مثل الانتفاخ أو تقلصات المعدة أو الإسهال.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.&nbsp;</p><p><strong>كيف يُعطى عقار&nbsp;زارزيو؟ وما الكمية التي عليَّ&nbsp;تلقيها؟&nbsp;</strong></p><p>يعطى عقار&nbsp;زارزيو&nbsp;عادةً&nbsp;في هيئة&nbsp;حَقْن يومي في النسيج أسفل الجلد مباشرةً&nbsp;(يُعرف ذلك بالحَقْن أسفل الجلد). يُمكِن أيضًا إعطاؤه في هيئة&nbsp;حَقْن يومي بطيء في الوريد (يُعرَف ذلك&nbsp;بالتَّسريب&nbsp;الوريدي). تتباين الجرعة المُعتادة وفقًا لوزنك والمرض الذي تعانيه. سيخبرك طبيبك بالكمية التي يجب عليك تلقيها من عقار&nbsp;زارزيو.&nbsp;</p><p>المرضى ممن خضعوا لزراعة نخاع عظمي بعد تلقي العلاج الكيميائي:&nbsp;</p><p>ستتلقى&nbsp;عادةً&nbsp;جرعتك الأولى من عقار&nbsp;زارزيو&nbsp;بعد 24 ساعة على الأقل من تلقيك العلاج الكيميائي وبعد 24 ساعة على الأقل من خضوعك لزراعة النخاع العظمي.&nbsp;</p><p>يُمكِن تعليمك، أنت أو&nbsp;الأشخاص الذين يتولون رعايتك، كيفية إعطاء الحَقْن أسفل الجلد بحيث يُمكِنك مواصلة علاجك في المنزل.&nbsp;&nbsp;<br />ومع ذلك، يجب أَلَّا تحاول القيام بذلك إذا لم تتلق تدريبًا ملائمًا أولاً&nbsp;من قبل مقدم الرعاية الصحية الخاص بك.&nbsp;</p><p><strong>إلى متى&nbsp;يجب علي تلقى عقار&nbsp;زارزيو؟&nbsp;</strong></p><p>ستحتاج إلى&nbsp;تلقي عقار&nbsp;زارزيو&nbsp;حتى يصبح عدد خلايا الدَّم البيضاء لديك طبيعيًّا. سيتم إجراء اختبارات دم بصفة منتظمة؛ لمراقبة عدد خلايا الدَّم البيضاء في جسمك. سيخبرك طبيبك بالمدة التي ستحتاجها لتلقي عقار&nbsp;زارزيو.&nbsp;</p><p>الاستخدام&nbsp;لدى&nbsp;الأطفال&nbsp;</p><p>يُستَخدَم عقار&nbsp;زارزيو&nbsp;لعلاج الأطفال ممن يتلقون العلاج الكيميائي أو ممن يُعانون انخفاضًا&nbsp;شديدًا&nbsp;في عدد خلايا الدَّم البيضاء (قلة خلايا العَدِلات). الجرعات بالنسبة للأطفال الذين يتلقون العلاج الكيميائي هي نفسها بالنسبة للبالغين.&nbsp;</p><p><strong>إذا استخدمت كمية أكثر مما يجب من عقار&nbsp;زارزيو</strong>&nbsp;</p><p>لا تقم بزيادة الجرعة التي أعطاها لك طبيبك. إذا اعتقدت أنك قد حَقَنت نفسك بكمية أكثر مما يجب من العقار، فاتصل&nbsp;بطبيبك بأسرع&nbsp;ما يُمكِن.&nbsp;</p><p><strong>إذا أغفلت استخدام عقار&nbsp;زارزيو&nbsp;</strong></p><p>إذا أغفلت عملية حَقْن، أو حَقَنت كمية أقل مما يجب، فاتصل بطبيبك بأسرع ما يُمكِن. لا تتلقى&nbsp;جرعة مضاعفة لتعويض أي جرعات قد تم إغفالها.&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك أو الممرض(ة).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.&nbsp;</p><p><strong>يُرجى إخبار طبيبك فورًا</strong>&nbsp;إذا حدث أي مما يلي أثناء العلاج:&nbsp;</p><ul><li><p>إذا تعرَّضت لأحد تفاعلات الحساسية ويشمل ذلك الضعف وهبوط ضغط الدَّم وصعوبة التنفس&nbsp;وتورُّم الوجه (تأقًا) والطفح الجلدي والطفح الجلدي المصحوب بحكة (أرتكاريا) وتورُّم الوجه أو الشفتين أو الفم أو اللسان أو الحَلْق (وذمة وعائية) وضيق التنفس.&nbsp;</p></li><li><p>إذا تعرَّضت لسعال وحُمّى وصعوبة في التَّنفس (ضيق التَّنفس)؛ إذ قد تكون هذه علامة على الإصابة بمتلازمة ضيق التَّنفس الحاد.&nbsp;</p></li><li><p>إذا&nbsp;أُصِبت بألم في الجزء العلوي الأيسر من البطن أو بألم أسفل الجهة اليسرى من القفص الصدري أو على طرف كتفك؛ إذ قد تكون هناك مشكلة لديك بالطحال [تضخُّم الطحال أو تمزُّق في الطحال].&nbsp;</p></li><li><p>إذا كنت تُعالَج من حالة مُزمِنة وشديدة من قلة خلايا العَدِلات وكان لديك دم في البول (بيلة دموية). قد يجري طبيبك اختبارًا للبول لديك بصفة منتظمة إذا تعرَّضت لهذا الأثر الجانبي أو إذا تم العثور على بروتين لديك في البول (بيلة بروتينية).&nbsp;</p></li><li><p>إذا كان لديك أي من التَّالي أو مزيج من الآثار الجانبية التَّالية:&nbsp;</p></li><li><p>تورُّم أو انتفاخ، قد يصاحبه تبوُّل بصورة أقل تكرارًا، صعوبة في التنفس، انتفاخ البطن وشعور&nbsp;بالامتلاء، وشعور عام بالتعب. تظهر هذه الأعراض بشكل عام بشكل سريع.&nbsp;</p></li></ul><p>قد تكون هذه أعراض لحالة&nbsp;تُسمى&nbsp;&quot;متلازمة التسرُّب الشعيري&quot; وهي حالة تسبب تسرب الدَّم من الأوعية الدموية الصغيرة إلى جسمك وتحتاج إلى العناية الطبية العاجلة.&nbsp;</p><ul><li><p>إذا كنت تعاني مزيجًا&nbsp;من أي من الأعراض التَّالية:&nbsp;</p></li><li><p>حُمّى أو ارتعاش أو شعور بالبرودة الشديدة أو ارتفاع معدل ضربات القلب أو ارتباك أو&nbsp;توهان&nbsp;أو ضيق&nbsp;بالتَّنفس أو ألم شديد أو شعور غير مريح وجلد متعرّق أو مُتَنَدٍّ&nbsp;بالعرق.&nbsp;</p></li></ul><p>قد تكون هذه أعراض لحالة&nbsp;تُسمى&nbsp;&quot;تعفُّن الدَّم&quot; (تُسمى أيضًا &quot;تسمم الدَّم&quot;)، وهي عدوى شديدة مصحوبة برد فعل التهابي للجسم بالكامل والتي يمكن أن تكون مُهَدِّدة للحياة وتحتاج إلى العناية الطبية العاجلة.&nbsp;</p><ul><li><p>إذا تعرضت لإصابة في الكُلى (التهاب&nbsp;كبيبات&nbsp;الكُلى). لُوحظ وجود إصابة في الكُلى في المرضى الذين تلقوا&nbsp;فيلجراستيم. اتصل بطبيبك فورًا إذا تعرَّضت لانتفاخ بالوجه أو الكاحلين،&nbsp;أو لاحظت&nbsp;وجود دم في البول أو بول بني اللون أو لاحظت أنك تتبول بمعدل أقل من المُعتاد</p></li><li><p>أحد الآثار الجانبية الشائعة لاستخدام&nbsp;فيلجراستيم&nbsp;هو الشعور بألم لديك بالعضلات أو العظام، وهو ما يُمكِن تخفيفه عن طريق تناوُل أدوية تسكين الألم الاعتيادية (المُسَكِّنات).&nbsp;لدى&nbsp;المرضى الذين يخضعون لزراعة خلايا جذعية أو&nbsp;نخاع عظمي، فقد تحدث&nbsp;إصابة بداء&nbsp;الطُّعْمِ&nbsp;حِيَالَ&nbsp;الثَّوِيّ&nbsp;-وهو استجابة خلايا المتبرع ضد المريض متلقي الزراعة؛ تتضمن العلامات والأعراض طفحًا جلديًّا على راحتي اليدين&nbsp;أو أخمصي القدمين والتهابات وقرحًا في الفم والأمعاء والكبد والجلد أو العينين والرئتين والمهبل والمفاصل.&nbsp;لُوحظ&nbsp;بشكل شائع جدًّا&nbsp;لدى&nbsp;المتبرعين بخلايا جذعية طبيعية زيادة في عدد خلايا الدَّم البيضاء وانخفاض في عدد الصفائح الدَّموية وهو ما يقلل قدرة الدَّم على التجلط (قلة الصَّفائح الدَّموية)،&nbsp;وسيتولى طبيبك مراقبة هذه الأمور.&nbsp;</p><p>الآثار الجانبية الشائعة جدًّا&nbsp;(قد تُؤثر على أكثر من 1 من بين كل 10 أشخاص)&nbsp;</p></li><li><p>انخفاض عدد الصفائح الدَّموية وهو ما يقلل قدرة الدَّم على التجلط (نقص الصَّفائح الدَّموية)&nbsp;</p></li><li><p>انخفاض عدد خلايا الدم الحمراء (فقر الدم)&nbsp;</p></li><li><p>صداع&nbsp;</p></li><li><p>إِسْهال&nbsp;</p></li><li><p>قيء&nbsp;</p></li><li><p>غثيان&nbsp;</p></li><li><p>حالة غير مُعتادة من تساقط الشعر أو ترققه (ثعلبة)&nbsp;</p></li><li><p>تعب (إرهاق)&nbsp;</p></li><li><p>قُرَح وتورُّم في بطانة الجهاز الهضمي الذي يمتد من الفم إلى فتحة الشرج (التهاب الغشاء المخاطي)&nbsp;</p></li><li><p>حُمى (ارتفاع درجة الحرارة)&nbsp;</p></li><li><p>الآثار الجانبية الشَّائعة&nbsp;(قد تُؤثر&nbsp;في ما&nbsp;يصل إلى 1 من بين كل 10 أشخاص)&nbsp;</p></li><li><p>التهاب الرئة (التهاب الشُّعَب الهوائية)&nbsp;</p></li><li><p>عدوى الجهاز&nbsp;التَّنفسي العلوي&nbsp;</p></li><li><p>عدوى الجهاز البولي&nbsp;</p></li><li><p>انخفاض&nbsp;الشهية&nbsp;</p></li><li><p>صعوبات في النوم (أَرَق)&nbsp;</p></li><li><p>دوخة&nbsp;</p></li><li><p>انخفاض الإحساس، لا سيَّما في الجلد (تدنّي&nbsp;الإحساس)&nbsp;</p></li><li><p>وخز أو تنميل باليدين أو القدمين (اضطرابات الإحساس)&nbsp;</p></li><li><p>انخفاض ضغط الدَّم&nbsp;</p></li><li><p>ارتفاع ضغط الدَّم&nbsp;</p></li><li><p>سعال&nbsp;</p></li><li><p>سعال مصحوب بدم (نَفْث الدَّم [سُعال دموي])&nbsp;</p></li><li><p>ألم لديك في الفم والحَلْق (ألم بالفم والبلعوم)&nbsp;</p></li><li><p>طفح جلدي&nbsp;</p></li><li><p>احمرار الجلد (حُمامي)&nbsp;</p></li><li><p>تقلصات عضلية&nbsp;</p></li><li><p>ألم&nbsp;عند&nbsp;التبوُّل (عُسْر التَّبَوُّل)&nbsp;</p></li><li><p>ألم بالصدر&nbsp;</p></li><li><p>ألم&nbsp;</p></li><li><p>ضعف مُعَمم (وهن)&nbsp;</p></li><li><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAYAAAANCAYAAACKCx+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAABeSURBVChTY6AI8ADxHiB+A8SGIAEQADFAAsVgHhTAVKIIggBI9Skg3g3E/4F4IRCDgQ8QgwRBCiSB+C5UDEwgGwNigyVAqkA6QDTIvpVADHcVSAXIfBAGq6YaYGAAANQaEGio4zPyAAAAAElFTkSuQmCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />شعور عام بالإعياء (توعُّك)&nbsp;&nbsp;</p></li><li><p>تورُّم باليدين والقدمين (وذمة طرفية)&nbsp;</p></li><li><p>زيادة بعض الإنزيمات في الدَّم&nbsp;</p></li><li><p>تغيُّرات في كيمياء الدَّم&nbsp;</p></li><li><p>تفاعلات نقل الدَّم&nbsp;</p></li><li><p>الآثار الجانبيَّة غير الشَّائعة&nbsp;(قد&nbsp;تُؤثر&nbsp;في ما&nbsp;يصل إلى 1 من بين كل 100 شخص)&nbsp;</p></li><li><p>زيادة عدد خلايا الدَّم البيضاء&nbsp;</p></li><li><p>تفاعلات حساسية (فرط الحساسية)&nbsp;</p></li><li><p>رفض النخاع العظمي المزروع (داء&nbsp;الطُّعْمِ&nbsp;حِيَالَ&nbsp;الثَّوِيّ)&nbsp;</p></li><li><p>ارتفاع مستويات حمض&nbsp;اليوريك&nbsp;في الدَّم، وهو ما قد يُسبب الإصابة بالنّقْرِس (فرط حمض&nbsp;اليوريك&nbsp;بالدَّم) (ارتفاع مستوى حمض&nbsp;اليوريك&nbsp;بالدَّم)&nbsp;</p></li><li><p>تلف كبدي ناجم عن انسداد الأوردة الصغيرة&nbsp;الموجوة&nbsp;في الكبد (داء الانسداد الوريدي)&nbsp;</p></li><li><p>عدم قيام الرئتين بوظائفهما على النحو الواجب، مما يُسبب عُسْر التَّنَفُّس&nbsp;(فشل الجهاز التنفسي)&nbsp;</p></li><li><p>تورم و/ أو تراكم السوائل في الرئتين (الوذمة الرئوية)&nbsp;</p></li><li><p>التهاب الرئتين (مرض الرئة الخلالي)&nbsp;</p></li><li><p>نتائج غير طبيعية لإجراء الأشعة السينية على الرئتين (ارتشاح رئوي)&nbsp;</p></li><li><p>نزيف من الرئة&nbsp;</p></li><li><p>نقص امتصاص الأكسجين في الرئة (نقص الأكسجين بالدَّم)&nbsp;</p></li><li><p>طفح جلدي غير مستو (طفح بقعي حطاطي)&nbsp;</p></li><li><p>مرض&nbsp;يُسبب&nbsp;انخفاض كثافة العظام وجعلها&nbsp;أضعف وأكثر هشاشة وعُرضة للكسر (هشاشة العظام)&nbsp;</p></li><li><p>تفاعلاً&nbsp;بموضع الحقن&nbsp;</p></li><li><p>&nbsp;</p><p>الآثار الجانبية النَّادرة&nbsp;(قد&nbsp;تُؤثر&nbsp;في ما&nbsp;يصل إلى شخص واحد من بين كل 1000 شخص):&nbsp;</p></li><li><p>ألم شديد في العظام أو الصدر أو الأمعاء أو المفاصل (أنيميا الخلايا المنجلية مع التعرُّض لأزمة)&nbsp;</p></li><li><p>تفاعل حساسية مفاجئ ومُهَدِّد للحياة (تفاعل&nbsp;تَأَقِيّ)&nbsp;</p></li><li><p>ألم وتورُّم في المفاصل، مماثل للنقرس (نقرس كاذب)&nbsp;</p></li><li><p>تغيُّر في كيفية تنظيم جسمك للسوائل داخله وقد يُؤدي إلى حدوث انتفاخ (اضطرابات في كمية السوائل)&nbsp;</p></li><li><p>التهاب الأوعية الدَّموية في الجلد (التهاب الأوعية الدَّموية الجلدية)&nbsp;</p></li><li><p>قُرَح بارزة ومؤلمة أرجوانية اللون على الأطراف وفي بعض الأحيان على الوجه والرقبة مصحوبة بحُمّى&nbsp;(متلازمة&nbsp;سويتس)&nbsp;</p></li><li><p>تفاقم التهاب المفاصل&nbsp;الروماتويدي&nbsp;</p></li><li><p>تغيُّر غير مُعتاد في البول&nbsp;</p></li><li><p>انخفاض كثافة العظام&nbsp;</p></li><li><p>التهاب الشريان الأورطي (الوعاء الدَّموي الكبير الذي ينقل الدَّم من القلب إلى الجسم)، انظر قسم: 2.&nbsp;</p></li><li><p>الإبلاغ عن الآثار الجانبية&nbsp;</p><p>إذا كان لديك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة.&nbsp;&nbsp;<br />ويشمل ذلك أي آثار جانبية محتملة غير&nbsp;تلك&nbsp;المدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة.&nbsp;</p><p><img alt="Text Box" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAYAAAANCAYAAACKCx+LAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAAzSURBVChTYyALSALxXSD+j4R9gJjBEIhBkjBQD8TIfDAACYAkMADICLAx6ICWxlAMGBgAK+sIskJi8BAAAAAASUVORK5CYIIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==" />ابلاغك عن الآثار الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء</p></li><li><p>نزيف من الأنف (الرعاف)&nbsp;</p></li><li><p>إمساك&nbsp;</p></li><li><p>ألم بالفم&nbsp;</p></li><li><p>تضخُّم&nbsp;الكبد&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.&nbsp;</p><p>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى ملصق السرنجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p>يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية).&nbsp;</p><p>احتفظ بالسرنجة المعبأة مسبقًا داخل العبوة الكرتونية الخارجية لحمايتها من الضَّوء.&nbsp;</p><p>لن يُلحِق التَّجميد العَرَضي ضررًا بعقار&nbsp;زارزيو.&nbsp;</p><p>يُمكِن إخراج السرنجة من الثلاجة وتركها في درجة حرارة الغرفة لمدة واحدة بحد أقصى 72 ساعة (لكن ليس في درجة حرارة تتجاوز 25 درجة مئوية). في نهاية هذه الفترة، يجب عدم وضع المُنتَج مرة أخرى في الثلاجة ويجب التَّخلص منه.&nbsp;</p><p>لا تستخدم هذا الدَّواء إذا لاحظت تغيُّر لونه أو&nbsp;أصبح&nbsp;ضبابيًا&nbsp;أو&nbsp;لاحظت&nbsp;وجود جسيمات به؛ إذ يجب أن يكون الدَّواء سائلاً&nbsp;صافيًا&nbsp;وعديم اللون أو مائلاً&nbsp;إلى&nbsp;الإصفرار&nbsp;قليلاً.&nbsp;</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><p>المادة الفعالة هي&nbsp;فيلجراستيم.&nbsp;</p></li></ul><p>عقار&nbsp;زارزيو&nbsp;30 مليون وحدة/ 0.5 مللي لتر محلول للحقن أو للتسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا: تحتوي كل سرنجة مُعبأة مُسبقًا على 30 مليون وحدة&nbsp;فيلجراستيم&nbsp;في 0.5 مللي لتر، بما يُعادِل 60 مليون وحدة/ مللي لتر.&nbsp;</p><p>عقار&nbsp;زارزيو&nbsp;48 مليون وحدة/ 0.5 مللي لتر محلول للحقن أو للتَّسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا: تحتوي كل سرنجة مُعبأة مُسبقًا على 48 مليون وحدة&nbsp;فيلجراستيم&nbsp;في 0.5 مللي لتر، بما يُعادِل 96 مليون وحدة/ مللي لتر.&nbsp;</p><ul><li><p>المكونات الأخرى هي حمض الجلوتاميك،&nbsp;سوربيتول&nbsp;(E420)،&nbsp;بوليسوربات&nbsp;80 وماء للحَقْن.&nbsp;</p></li><li><p>قد يحتوي غطاء إبرة السرنجة على المطاط الجاف (مادة&nbsp;اللاتكس)</p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عقار&nbsp;زارزيو&nbsp;عبارة عن محلول صافٍ&nbsp;وعديم اللون مائل إلى&nbsp;الإصفرار&nbsp;قليلاً&nbsp;للحَقْن أو للتَّسريب في&nbsp;سرنجات&nbsp;معبأة مسبقًا.&nbsp;</p><p>يتوفر عقار&nbsp;زارزيو&nbsp;في عبوات تحتوي على 1&nbsp;أو 3 أو 5 أو 10&nbsp;سرنجات&nbsp;معبأة مسبقًا مع إبرة حَقْن ومع أو بدون آلية أمان للإبرة.&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التَّسويق&nbsp;</strong></p><p>شركة&nbsp;ساندوز&nbsp;المحدودة&nbsp;</p><p>10&nbsp;شارع&nbsp;بايوشيمي&nbsp;(المستحضرات الحيوية)&nbsp;</p><p>6250&nbsp;كوندل&nbsp;</p><p>النمسا</p><p><strong>جهة التَّصنيع&nbsp;</strong></p><p>شركة&nbsp;ساندوز&nbsp;المحدودة&nbsp;</p><p>10&nbsp;شارع&nbsp;بيوشيمي&nbsp;شتراسه&nbsp;</p><p>6336&nbsp;لانجكامبفين&nbsp;</p><p>النمسا&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zarzio 30  MU/0.5  ml  solution for  injection or  infusion  in pre-filled  syringe Zarzio 48  MU/0.5  ml  solution for  injection or  infusion  in pre-filled  syringe 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zarzio 30  MU/0.5  ml  solution for  injection or  infusion  in pre-filled  syringe Each  ml of  solution  contains  60  million  units  (MU)  (equivalent  to 600  micrograms  [μg])  filgrastim*. 
Each  pre-filled syringe  contains  30  MU  (equivalent  to 300  μg)  filgrastim  in 0.5  ml.
 Zarzio 48  MU/0.5  ml  solution for  injection or  infusion  in pre-filled  syringe Each  ml of  solution  contains  96  million  units  (MU)  (equivalent  to 960  micrograms  [μg])  filgrastim*. 
Each  pre-filled syringe  contains  48  MU  (equivalent  to 480  μg)  filgrastim  in 0.5  ml. * recombinant  methionylated human granulocyte-colony  stimulating  factor  (G-CSF)  produced  in E.  coli  by  recombinant  DNA  technology. Excipient with  known effect Each  ml of  solution  contains  50  mg  sorbitol  (E420). For  the full  list  of  excipients,  see  section  6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution  for  injection or  infusion  in  pre-filled  syringe  (injection  or  infusion). Clear,  colourless  to  slightly  yellowish solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Reduction &nbsp;in &nbsp;the &nbsp;duration of &nbsp;neutropenia &nbsp;and the &nbsp;incidence &nbsp;of &nbsp;febrile &nbsp;neutropenia &nbsp;in patients treated with established &nbsp;cytotoxic &nbsp;chemotherapy &nbsp;for &nbsp;malignancy &nbsp;(with &nbsp;the &nbsp;exception of &nbsp;chronic myeloid leukaemia &nbsp;and myelodysplastic &nbsp;syndromes) &nbsp;and reduction &nbsp;in &nbsp;the &nbsp;duration &nbsp;of neutropenia &nbsp;in patients &nbsp;undergoing &nbsp;myeloablative &nbsp;therapy &nbsp;followed by &nbsp;bone &nbsp;marrow transplantation &nbsp;considered &nbsp;to &nbsp;be at &nbsp;increased &nbsp;risk &nbsp;of &nbsp;prolonged &nbsp;severe &nbsp;neutropenia. The &nbsp;safety &nbsp;and &nbsp;efficacy &nbsp;of &nbsp;filgrastim &nbsp;are &nbsp;similar &nbsp;in &nbsp;adults and &nbsp;children &nbsp;receiving &nbsp;cytotoxic chemotherapy.</p><p>- Mobilisation &nbsp;of &nbsp;peripheral &nbsp;blood progenitor &nbsp;cells &nbsp;(PBPCs).</p><p>- In patients, children &nbsp;or &nbsp;adults, with severe &nbsp;congenital, &nbsp;cyclic, or &nbsp;idiopathic &nbsp;neutropenia &nbsp;with an absolute &nbsp;neutrophil &nbsp;count &nbsp;(ANC) &nbsp;of &nbsp;&le; &nbsp;0.5 &nbsp;x &nbsp;109/l, &nbsp;and &nbsp;a history &nbsp;of &nbsp;severe &nbsp;or &nbsp;recurrent &nbsp;infections, long &nbsp;term &nbsp;administration of &nbsp;filgrastim &nbsp;is &nbsp;indicated to &nbsp;increase &nbsp;neutrophil &nbsp;counts &nbsp;and to reduce the &nbsp;incidence &nbsp;and duration &nbsp;of &nbsp;infection-related &nbsp;events. - - - Treatment &nbsp;of &nbsp;persistent &nbsp;neutropenia (ANC &nbsp;&le; &nbsp;1.0 &nbsp;x &nbsp;109/l) &nbsp;in &nbsp;patients with &nbsp;advanced &nbsp;HIV infection, &nbsp;in order &nbsp;to &nbsp;reduce &nbsp;the &nbsp;risk &nbsp;of &nbsp;bacterial &nbsp;infections &nbsp;when other &nbsp;options &nbsp;to &nbsp;manage neutropenia &nbsp;are &nbsp;inappropriate.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim &nbsp;therapy &nbsp;should only &nbsp;be &nbsp;given in collaboration with &nbsp;an oncology &nbsp;centre &nbsp;which has experience in &nbsp;G-CSF &nbsp;treatment &nbsp;and &nbsp;haematology &nbsp;and &nbsp;has the necessary &nbsp;diagnostic facilities. &nbsp;The mobilisation and &nbsp;apheresis &nbsp;procedures &nbsp;should &nbsp;be &nbsp;performed in collaboration &nbsp;with an &nbsp;oncologyhaematology &nbsp;centre &nbsp;with acceptable &nbsp;experience &nbsp;in this &nbsp;field and where &nbsp;the &nbsp;monitoring &nbsp;of haematopoietic progenitor &nbsp;cells can &nbsp;be &nbsp;correctly &nbsp;performed. Established &nbsp;cytotoxic chemotherapy Posology The &nbsp;recommended dose &nbsp;of &nbsp;filgrastim &nbsp;is &nbsp;0.5 &nbsp;MU/kg/day &nbsp;(5 &nbsp;&mu;g/kg/day). The &nbsp;first &nbsp;dose &nbsp;of &nbsp;filgrastim should be &nbsp;administered at &nbsp;least &nbsp;24 &nbsp;hours &nbsp;after &nbsp;cytotoxic chemotherapy. &nbsp;In &nbsp;randomised &nbsp;clinical &nbsp;trials, &nbsp;a subcutaneous &nbsp;dose &nbsp;of &nbsp;230 &nbsp;&mu;g/m2/day &nbsp;(4.0 to 8.4 &nbsp;&mu;g/kg/day) &nbsp;was &nbsp;used. Daily &nbsp;dosing &nbsp;with &nbsp;filgrastim &nbsp;should continue &nbsp;until &nbsp;the &nbsp;expected &nbsp;neutrophil &nbsp;nadir &nbsp;is &nbsp;passed and the neutrophil &nbsp;count &nbsp;has &nbsp;recovered &nbsp;to the &nbsp;normal &nbsp;range. Following &nbsp;established chemotherapy &nbsp;for &nbsp;solid tumours, lymphomas, and lymphoid leukaemia, it &nbsp;is &nbsp;expected that &nbsp;the &nbsp;duration of &nbsp;treatment &nbsp;required to fulfil &nbsp;these &nbsp;criteria will &nbsp;be up &nbsp;to &nbsp;14 &nbsp;days. Following &nbsp;induction and consolidation treatment &nbsp;for &nbsp;acute myeloid leukaemia &nbsp;the &nbsp;duration &nbsp;of &nbsp;treatment &nbsp;may &nbsp;be &nbsp;substantially &nbsp;longer &nbsp;(up to 38 &nbsp;days) &nbsp;depending &nbsp;on the &nbsp;type, &nbsp;dose &nbsp;and schedule &nbsp;of &nbsp;cytotoxic &nbsp;chemotherapy &nbsp;used. In &nbsp;patients receiving &nbsp;cytotoxic chemotherapy, &nbsp;a transient &nbsp;increase in &nbsp;neutrophil &nbsp;counts &nbsp;is &nbsp;typically &nbsp;seen 1 &nbsp;- &nbsp;2 &nbsp;days after &nbsp;initiation &nbsp;of &nbsp;filgrastim &nbsp;therapy. &nbsp;However, &nbsp;for &nbsp;a &nbsp;sustained &nbsp;therapeutic response, filgrastim &nbsp;therapy &nbsp;should &nbsp;not &nbsp;be &nbsp;discontinued before &nbsp;the &nbsp;expected nadir &nbsp;has &nbsp;passed &nbsp;and the &nbsp;neutrophil count &nbsp;has &nbsp;recovered &nbsp;to the &nbsp;normal &nbsp;range. Premature &nbsp;discontinuation of &nbsp;filgrastim &nbsp;therapy, prior &nbsp;to &nbsp;the time &nbsp;of &nbsp;the &nbsp;expected neutrophil &nbsp;nadir, &nbsp;is &nbsp;not &nbsp;recommended. Method of &nbsp;administration Filgrastim &nbsp;may &nbsp;be given &nbsp;as a daily &nbsp;subcutaneous &nbsp;injection &nbsp;or &nbsp;as a daily &nbsp;intravenous &nbsp;infusion &nbsp;diluted &nbsp;in 5% glucose &nbsp;solution given &nbsp;over &nbsp;30 &nbsp;minutes (see &nbsp;section &nbsp;6.6). The &nbsp;subcutaneous &nbsp;route &nbsp;is &nbsp;preferred in most &nbsp;cases. &nbsp;There is some evidence &nbsp;from &nbsp;a &nbsp;study &nbsp;of &nbsp;single &nbsp;dose &nbsp;administration that &nbsp;intravenous &nbsp;dosing may &nbsp;shorten &nbsp;the &nbsp;duration of &nbsp;effect. &nbsp;The &nbsp;clinical &nbsp;relevance &nbsp;of &nbsp;this &nbsp;finding &nbsp;to multiple &nbsp;dose administration is &nbsp;not &nbsp;clear. The &nbsp;choice &nbsp;of &nbsp;route &nbsp;should depend on &nbsp;the &nbsp;individual &nbsp;clinical &nbsp;circumstance. In patients &nbsp;treated with myeloablative &nbsp;therapy &nbsp;followed &nbsp;by &nbsp;bone &nbsp;marrow &nbsp;transplantation Posology The &nbsp;recommended starting &nbsp;dose &nbsp;of &nbsp;filgrastim &nbsp;is &nbsp;1.0 &nbsp;MU/kg/day &nbsp;(10 &nbsp;&mu;g/kg/day). The &nbsp;first &nbsp;dose &nbsp;of filgrastim &nbsp;should &nbsp;be administered &nbsp;at &nbsp;least &nbsp;24 &nbsp;hours &nbsp;following &nbsp;cytotoxic chemotherapy &nbsp;and &nbsp;at &nbsp;least 24 &nbsp;hours &nbsp;after &nbsp;bone &nbsp;marrow &nbsp;infusion. Once &nbsp;the &nbsp;neutrophil &nbsp;nadir &nbsp;has &nbsp;been passed, &nbsp;the &nbsp;daily &nbsp;dose &nbsp;of &nbsp;filgrastim &nbsp;should be &nbsp;titrated &nbsp;against &nbsp;the neutrophil &nbsp;response &nbsp;as &nbsp;follows:&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:537px"><tbody><tr><td style="width:218px">Neutrophil &nbsp;count</td><td style="width:315px">Filgrastim &nbsp;dose &nbsp;adjustment</td></tr><tr><td style="width:218px">&gt; 1.0 x 10 9 /l &nbsp;for &nbsp;3 consecutive days</td><td style="width:315px">Reduce &nbsp;to &nbsp;0.5</td></tr><tr><td style="width:218px">Then, if &nbsp;ANC &nbsp;remains &nbsp;&gt; 1.0 3 x 10 9 /l &nbsp;for MU/kg/day (5 &mu;g/kg/day)</td><td style="width:315px">Discontinue filgrastim</td></tr><tr><td style="width:218px">If &nbsp;the ANC &nbsp;decreases &nbsp;to &nbsp;&lt; Discontinue filgrastim &nbsp; 1.0 x 10 9 /l &nbsp;during &nbsp;the &nbsp;treatment &nbsp;period, the dose of filgrastim should &nbsp;be &nbsp;reescalated &nbsp;according &nbsp;to &nbsp;theabove steps</td><td style="width:315px">&nbsp;</td></tr><tr><td style="width:218px">ANC = absolute &nbsp;neutrophil &nbsp;count</td><td style="width:315px">&nbsp;</td></tr></tbody></table><p>Method of &nbsp;administration Filgrastim &nbsp;may &nbsp;be given &nbsp;as a 30 &nbsp;minute &nbsp;or &nbsp;24 &nbsp;hour &nbsp;intravenous &nbsp;infusion or &nbsp;given by &nbsp;continuous 24 &nbsp;hour &nbsp;subcutaneous &nbsp;infusion. Filgrastim &nbsp;should be &nbsp;diluted in &nbsp;20 &nbsp;ml &nbsp;of &nbsp;5% &nbsp;glucose &nbsp;solution (see section &nbsp;6.6). For &nbsp;the &nbsp;mobilisation &nbsp;of &nbsp;PBPCs &nbsp;in patients &nbsp;undergoing &nbsp;myelosuppressive &nbsp;or &nbsp;myeloablative &nbsp;therapy followed by &nbsp;autologous &nbsp;PBPC &nbsp;transplantation Posology The &nbsp;recommended dose &nbsp;of &nbsp;filgrastim &nbsp;for &nbsp;PBPC &nbsp;mobilisation when used alone &nbsp;is 1.0 &nbsp;MU/kg/day &nbsp;(10 &nbsp;&mu;g/kg/day) &nbsp;for &nbsp;5 &nbsp;- &nbsp;7 &nbsp;consecutive &nbsp;days. Timing &nbsp;of &nbsp;leukapheresis: 1 &nbsp;or &nbsp;2 &nbsp;leukaphereses on &nbsp;days &nbsp;5 and &nbsp;6 are &nbsp;often &nbsp;sufficient. In other &nbsp;circumstances, additional leukaphereses may &nbsp;be necessary. &nbsp;Filgrastim &nbsp;dosing &nbsp;should &nbsp;be maintained &nbsp;until &nbsp;the last &nbsp;leukapheresis. The &nbsp;recommended dose &nbsp;of &nbsp;filgrastim &nbsp;for &nbsp;PBPC &nbsp;mobilisation after &nbsp;myelosuppressive &nbsp;chemotherapy &nbsp;is 0.5 &nbsp;MU/kg/day &nbsp;(5 &nbsp;&mu;g/kg/day) &nbsp;from &nbsp;the &nbsp;first &nbsp;day &nbsp;after &nbsp;completion of &nbsp;chemotherapy &nbsp;until &nbsp;the &nbsp;expected neutrophil &nbsp;nadir &nbsp;is &nbsp;passed and the &nbsp;neutrophil &nbsp;count &nbsp;has &nbsp;recovered &nbsp;to &nbsp;the normal &nbsp;range. &nbsp;Leukapheresis should be &nbsp;performed during &nbsp;the &nbsp;period when &nbsp;the &nbsp;ANC &nbsp;rises &nbsp;from &nbsp;&lt; &nbsp;0.5 &nbsp;x &nbsp;109/l &nbsp;to &nbsp;&gt; &nbsp;5.0 &nbsp;x &nbsp;109/l. &nbsp;For patients &nbsp;who have &nbsp;not &nbsp;had extensive &nbsp;chemotherapy, one &nbsp;leukapheresis &nbsp;is &nbsp;often &nbsp;sufficient. &nbsp;In other circumstances, &nbsp;additional &nbsp;leukaphereses &nbsp;are recommended. Method of &nbsp;administration Filgrastim &nbsp;for &nbsp;PBPC &nbsp;mobilisation when used alone: Filgrastim &nbsp;may &nbsp;be given &nbsp;as a 24 &nbsp;hour &nbsp;subcutaneous &nbsp;continuous &nbsp;infusion or &nbsp;subcutaneous &nbsp;injection. For infusions &nbsp;filgrastim &nbsp;should be &nbsp;diluted in &nbsp;20 &nbsp;ml &nbsp;of &nbsp;5% &nbsp;glucose solution &nbsp;(see section &nbsp;6.6). Filgrastim &nbsp;for &nbsp;PBPC &nbsp;mobilisation after &nbsp;myelosuppressive &nbsp;chemotherapy: Filgrastim &nbsp;should be &nbsp;given &nbsp;by &nbsp;subcutaneous &nbsp;injection. For &nbsp;the &nbsp;mobilisation &nbsp;of &nbsp;PBPCs &nbsp;in normal &nbsp;donors &nbsp;prior &nbsp;to allogeneic &nbsp;PBPC &nbsp;transplantation Posology For &nbsp;PBPC &nbsp;mobilisation &nbsp;in normal &nbsp;donors, filgrastim &nbsp;should be &nbsp;administered &nbsp;at 1.0 &nbsp;MU/kg/day &nbsp;(10 &nbsp;&mu;g/kg/day) &nbsp;for &nbsp;4 &nbsp;- &nbsp;5 &nbsp;consecutive days. &nbsp;Leukapheresis &nbsp;should &nbsp;be started &nbsp;at &nbsp;day &nbsp;5 and continued until &nbsp;day &nbsp;6 if &nbsp;needed in &nbsp;order &nbsp;to collect &nbsp;4 &nbsp;x &nbsp;106 &nbsp;CD34+ &nbsp;cells/kg &nbsp;recipient &nbsp;bodyweight. Method of &nbsp;administration Filgrastim &nbsp;should be &nbsp;given &nbsp;by &nbsp;subcutaneous &nbsp;injection. In &nbsp;patients with &nbsp;severe chronic neutropenia &nbsp;(SCN) Posology Congenital &nbsp;neutropenia The &nbsp;recommended starting &nbsp;dose &nbsp;is &nbsp;1.2 &nbsp;MU/kg/day &nbsp;(12 &nbsp;&mu;g/kg/day) &nbsp;as &nbsp;a &nbsp;single &nbsp;dose &nbsp;or &nbsp;in &nbsp;divided doses. Idiopathic or cyclic neutropenia The &nbsp;recommended starting &nbsp;dose &nbsp;is &nbsp;0.5 &nbsp;MU/kg/day &nbsp;(5 &nbsp;&mu;g/kg/day) &nbsp;as &nbsp;a &nbsp;single &nbsp;dose &nbsp;or &nbsp;in divided &nbsp;doses. Dose &nbsp;adjustment Filgrastim &nbsp;should be &nbsp;administered daily &nbsp;by &nbsp;subcutaneous &nbsp;injection until &nbsp;the &nbsp;neutrophil &nbsp;count &nbsp;has reached and can be &nbsp;maintained at &nbsp;more &nbsp;than 1.5 &nbsp;x &nbsp;109/l. When &nbsp;the &nbsp;response &nbsp;has &nbsp;been obtained, &nbsp;the&nbsp;minimal &nbsp;effective &nbsp;dose &nbsp;to &nbsp;maintain &nbsp;this &nbsp;level &nbsp;should &nbsp;be &nbsp;established. Long-term &nbsp;daily &nbsp;administration &nbsp;is required to maintain an &nbsp;adequate &nbsp;neutrophil &nbsp;count. After &nbsp;1 &nbsp;- &nbsp;2 weeks &nbsp;of &nbsp;therapy, the &nbsp;initial &nbsp;dose &nbsp;may be &nbsp;doubled or &nbsp;halved depending &nbsp;upon the &nbsp;patient&#39;s &nbsp;response. Subsequently &nbsp;the &nbsp;dose &nbsp;may &nbsp;be individually adjusted &nbsp;every 1 &nbsp;- &nbsp;2 &nbsp;weeks &nbsp;to &nbsp;maintain &nbsp;the &nbsp;average &nbsp;neutrophil &nbsp;count &nbsp;between 1.5 &nbsp;x &nbsp;109/l and 10 &nbsp;x &nbsp;109/l. A &nbsp;faster &nbsp;schedule &nbsp;of &nbsp;dose &nbsp;escalation may &nbsp;be &nbsp;considered in &nbsp;patients &nbsp;presenting &nbsp;with severe &nbsp;infections. &nbsp;In &nbsp;clinical &nbsp;trials, &nbsp;97% &nbsp;of &nbsp;patients who &nbsp;responded &nbsp;had &nbsp;a complete &nbsp;response &nbsp;at &nbsp;doses &le; &nbsp;24 &nbsp;&mu;g/kg/day. The &nbsp;long-term &nbsp;safety &nbsp;of &nbsp;filgrastim &nbsp;administration above &nbsp;24 &nbsp;&mu;g/kg/day &nbsp;in patients &nbsp;with SCN has not &nbsp;been &nbsp;established. Method of &nbsp;administration Congenital, idiopathic &nbsp;or &nbsp;cyclic &nbsp;neutropenia: &nbsp;Filgrastim &nbsp;should be &nbsp;given by &nbsp;subcutaneous &nbsp;injection. In patients &nbsp;with HIV &nbsp;infection Posology For reversal &nbsp;of &nbsp;neutropenia The &nbsp;recommended starting &nbsp;dose &nbsp;of &nbsp;filgrastim &nbsp;is &nbsp;0.1 &nbsp;MU/kg/day &nbsp;(1 &nbsp;&mu;g/kg/day), with titration up &nbsp;to a maximum &nbsp;of &nbsp;0.4 &nbsp;MU/kg/day &nbsp;(4 &nbsp;&mu;g/kg/day) &nbsp;until &nbsp;a &nbsp;normal &nbsp;neutrophil &nbsp;count &nbsp;is &nbsp;reached and &nbsp;can be maintained &nbsp;(ANC &nbsp;&gt; &nbsp;2.0 &nbsp;x &nbsp;109/l). &nbsp;In &nbsp;clinical &nbsp;studies, &gt; &nbsp;90% &nbsp;of &nbsp;patients &nbsp;responded at &nbsp;these &nbsp;doses, achieving &nbsp;reversal &nbsp;of &nbsp;neutropenia in &nbsp;a median &nbsp;of &nbsp;2 &nbsp;days. In a &nbsp;small &nbsp;number &nbsp;of &nbsp;patients &nbsp;(&lt; &nbsp;10%), doses &nbsp;up to &nbsp;1.0 &nbsp;MU/kg/day &nbsp;(10 &nbsp;&mu;g/kg/day) &nbsp;were &nbsp;required to achieve reversal &nbsp;of &nbsp;neutropenia. For &nbsp;maintaining &nbsp;normal &nbsp;neutrophil &nbsp;counts When reversal &nbsp;of &nbsp;neutropenia has been &nbsp;achieved, &nbsp;the minimal &nbsp;effective dose &nbsp;to &nbsp;maintain &nbsp;a normal neutrophil &nbsp;count &nbsp;should be &nbsp;established. Initial &nbsp;dose &nbsp;adjustment &nbsp;to &nbsp;alternate &nbsp;day &nbsp;dosing &nbsp;with 30 &nbsp;MU/day &nbsp;(300 &nbsp;&mu;g/day) &nbsp;is &nbsp;recommended. Further &nbsp;dose adjustment &nbsp;may &nbsp;be necessary, &nbsp;as determined by &nbsp;the &nbsp;patient&#39;s &nbsp;ANC, to maintain &nbsp;the &nbsp;neutrophil &nbsp;count &nbsp;at &nbsp;&gt; &nbsp;2.0 &nbsp;x &nbsp;109/l. In clinical &nbsp;studies, dosing &nbsp;with 30 &nbsp;MU/day &nbsp;(300 &nbsp;&mu;g/day) &nbsp;on 1 &nbsp;- &nbsp;7 &nbsp;days per &nbsp;week &nbsp;was required &nbsp;to &nbsp;maintain &nbsp;the ANC &nbsp;&gt; &nbsp;2.0 &nbsp;x &nbsp;109/l, &nbsp;with the &nbsp;median &nbsp;dose &nbsp;frequency &nbsp;being &nbsp;3 &nbsp;days &nbsp;per &nbsp;week. Long-term &nbsp;administration may &nbsp;be &nbsp;required &nbsp;to maintain &nbsp;the &nbsp;ANC &nbsp;&gt; &nbsp;2.0 &nbsp;x &nbsp;109/l. Method of &nbsp;administration Reversal &nbsp;of &nbsp;neutropenia &nbsp;or &nbsp;maintaining &nbsp;normal &nbsp;neutrophil &nbsp;counts: &nbsp;Filgrastim &nbsp;should be &nbsp;given by subcutaneous &nbsp;injection. Elderly Clinical &nbsp;trials with &nbsp;filgrastim &nbsp;have included &nbsp;a small &nbsp;number &nbsp;of &nbsp;elderly &nbsp;patients but &nbsp;special &nbsp;studies have not &nbsp;been performed in &nbsp;this &nbsp;group and therefore &nbsp;specific &nbsp;dosage &nbsp;recommendations &nbsp;cannot &nbsp;be &nbsp;made. Renal &nbsp;impairment Studies &nbsp;of &nbsp;filgrastim &nbsp;in &nbsp;patients &nbsp;with &nbsp;severe &nbsp;impairment &nbsp;of &nbsp;renal or &nbsp;hepatic &nbsp;function &nbsp;demonstrate &nbsp;that it exhibits &nbsp;a &nbsp;similar &nbsp;pharmacokinetic &nbsp;and &nbsp;pharmacodynamic &nbsp;profile &nbsp;to &nbsp;that &nbsp;seen in normal &nbsp;individuals. Dose &nbsp;adjustment &nbsp;is not &nbsp;required &nbsp;in &nbsp;these circumstances. Paediatric &nbsp;use &nbsp;in &nbsp;the SCN &nbsp;and &nbsp;cancer &nbsp;settings Sixty-five &nbsp;percent &nbsp;of &nbsp;the &nbsp;patients &nbsp;studied in &nbsp;the &nbsp;SCN &nbsp;trial &nbsp;program &nbsp;were &nbsp;under &nbsp;18 &nbsp;years of &nbsp;age. &nbsp;The efficacy &nbsp;of &nbsp;treatment &nbsp;was clear &nbsp;for &nbsp;this age-group, which included most &nbsp;patients &nbsp;with congenital neutropenia. &nbsp;There were no &nbsp;differences &nbsp;in &nbsp;the safety &nbsp;profiles &nbsp;for &nbsp;paediatric patients treated &nbsp;for &nbsp;SCN.&nbsp;</p><p>Data &nbsp;from &nbsp;clinical &nbsp;studies in &nbsp;paediatric patients indicate that &nbsp;the safety &nbsp;and &nbsp;efficacy &nbsp;of &nbsp;filgrastim &nbsp;are similar &nbsp;in &nbsp;both &nbsp;adults &nbsp;and &nbsp;children &nbsp;receiving &nbsp;cytotoxic &nbsp;chemotherapy. The &nbsp;dosage recommendations in &nbsp;paediatric patients are &nbsp;the same as those &nbsp;in &nbsp;adults &nbsp;receiving myelosuppressive &nbsp;cytotoxic &nbsp;chemotherapy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity  to  the active substance or  to  any  of  the excipients listed  in  section  6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special &nbsp;warnings &nbsp;and &nbsp;precautions across indications Hypersensitivity Hypersensitivity, including &nbsp;anaphylactic &nbsp;reactions, occurring &nbsp;on initial &nbsp;or &nbsp;subsequent &nbsp;treatment &nbsp;has been &nbsp;reported &nbsp;in &nbsp;patients treated &nbsp;with &nbsp;filgrastim. &nbsp;Permanently &nbsp;discontinue &nbsp;Zarzio &nbsp;in &nbsp;patients &nbsp;with clinically &nbsp;significant hypersensitivity. &nbsp;Do &nbsp;not administer &nbsp;Zarzio &nbsp;to &nbsp;patients &nbsp;with &nbsp;a &nbsp;history &nbsp;of hypersensitivity &nbsp;to &nbsp;filgrastim &nbsp;or &nbsp;pegfilgrastim. Pulmonary &nbsp;adverse &nbsp;effects Pulmonary &nbsp;adverse &nbsp;effects, &nbsp;in &nbsp;particular &nbsp;interstitial &nbsp;lung &nbsp;disease, &nbsp;have been &nbsp;reported &nbsp;after &nbsp;G-CSF administration. &nbsp;Patients &nbsp;with a &nbsp;recent &nbsp;history &nbsp;of &nbsp;lung &nbsp;infiltrates &nbsp;or &nbsp;pneumonia &nbsp;may &nbsp;be &nbsp;at &nbsp;higher &nbsp;risk. The &nbsp;onset &nbsp;of &nbsp;pulmonary &nbsp;signs, such as &nbsp;cough, fever &nbsp;and dyspnoea &nbsp;in association &nbsp;with &nbsp;radiological signs &nbsp;of &nbsp;pulmonary &nbsp;infiltrates &nbsp;and &nbsp;deterioration &nbsp;in pulmonary &nbsp;function may &nbsp;be &nbsp;preliminary &nbsp;signs &nbsp;of acute &nbsp;respiratory &nbsp;distress &nbsp;syndrome &nbsp;(ARDS). Filgrastim &nbsp;should be &nbsp;discontinued &nbsp;and appropriate treatment &nbsp;given &nbsp;in &nbsp;these cases. Glomerulonephritis Glomerulonephritis &nbsp;has &nbsp;been reported in patients &nbsp;receiving &nbsp;filgrastim &nbsp;or &nbsp;pegfilgrastim. Generally, events &nbsp;of &nbsp;glomerulonephritis &nbsp;resolved after &nbsp;dose &nbsp;reduction or &nbsp;withdrawal &nbsp;of &nbsp;filgrastim &nbsp;or &nbsp;pegfilgrastim. Urinalysis &nbsp;monitoring &nbsp;is &nbsp;recommended. Capillary &nbsp;leak &nbsp;syndrome Capillary &nbsp;leak &nbsp;syndrome, &nbsp;which &nbsp;can &nbsp;be life-threatening &nbsp;if &nbsp;treatment &nbsp;is &nbsp;delayed, &nbsp;has &nbsp;been &nbsp;reported &nbsp;after granulocyte &nbsp;colony-stimulating &nbsp;factor &nbsp;administration &nbsp;and is &nbsp;characterised by &nbsp;hypotension, hypoalbuminaemia, oedema &nbsp;and hemoconcentration. Patients &nbsp;who develop symptoms &nbsp;of &nbsp;capillary &nbsp;leak syndrome &nbsp;should be &nbsp;closely &nbsp;monitored &nbsp;and &nbsp;receive &nbsp;standard &nbsp;symptomatic &nbsp;treatment, which may include &nbsp;a need &nbsp;for &nbsp;intensive &nbsp;care &nbsp;(see section &nbsp;4.8). Splenomegaly &nbsp;and Splenic &nbsp;rupture Generally &nbsp;asymptomatic cases of &nbsp;splenomegaly &nbsp;and &nbsp;cases of &nbsp;splenic &nbsp;rupture &nbsp;have &nbsp;been &nbsp;reported &nbsp;in patients &nbsp;and normal &nbsp;donors &nbsp;following &nbsp;administration &nbsp;of &nbsp;filgrastim. &nbsp;Some cases of &nbsp;splenic &nbsp;rupture were fatal. &nbsp;Therefore, spleen size &nbsp;should be &nbsp;carefully &nbsp;monitored (e.g. clinical &nbsp;examination, ultrasound). A diagnosis &nbsp;of &nbsp;splenic &nbsp;rupture &nbsp;should be &nbsp;considered &nbsp;in donors &nbsp;and/or &nbsp;patients &nbsp;reporting &nbsp;left &nbsp;upper abdominal &nbsp;pain &nbsp;or &nbsp;shoulder &nbsp;tip &nbsp;pain. &nbsp;Dose reductions &nbsp;of &nbsp;filgrastim &nbsp;have been &nbsp;noted to slow &nbsp;or &nbsp;stop the progression of &nbsp;splenic &nbsp;enlargement &nbsp;in &nbsp;patients with &nbsp;severe chronic &nbsp;neutropenia, and in 3% &nbsp;of &nbsp;patients &nbsp;a splenectomy &nbsp;was required. Malignant &nbsp;cell &nbsp;growth G-CSF &nbsp;can promote &nbsp;growth &nbsp;of &nbsp;myeloid cells &nbsp;in &nbsp;vitro &nbsp;and &nbsp;similar &nbsp;effects &nbsp;may &nbsp;be seen &nbsp;on &nbsp;some nonmyeloid &nbsp;cells &nbsp;in &nbsp;vitro.&nbsp;</p><p>Myelodysplastic syndrome or &nbsp;Chronic &nbsp;myeloid &nbsp;leukemia The &nbsp;safety &nbsp;and efficacy &nbsp;of &nbsp;filgrastim &nbsp;administration in &nbsp;patients &nbsp;with myelodysplastic &nbsp;syndrome, or chronic &nbsp;myelogenous &nbsp;leukaemia &nbsp;have &nbsp;not &nbsp;been established. Filgrastim &nbsp;is &nbsp;not &nbsp;indicated &nbsp;for &nbsp;use &nbsp;in &nbsp;these conditions. Particular &nbsp;care &nbsp;should be &nbsp;taken to distinguish the &nbsp;diagnosis &nbsp;of &nbsp;blast &nbsp;transformation of chronic myeloid &nbsp;leukaemia from &nbsp;acute myeloid &nbsp;leukaemia. Acute &nbsp;myeloid &nbsp;leukaemia In &nbsp;view &nbsp;of &nbsp;limited &nbsp;safety &nbsp;and &nbsp;efficacy &nbsp;data in &nbsp;patients &nbsp;with &nbsp;secondary &nbsp;acute myelogenous leukaemia (AML), &nbsp;filgrastim &nbsp;should be &nbsp;administered with caution. &nbsp;The safety &nbsp;and &nbsp;efficacy &nbsp;of &nbsp;filgrastim administration in &nbsp;de &nbsp;novo &nbsp;AML &nbsp;patients aged &nbsp;&lt; &nbsp;55 &nbsp;years &nbsp;with &nbsp;good cytogenetics &nbsp;[t(8;21), &nbsp;t(15;17), and inv(16)] &nbsp;have &nbsp;not &nbsp;been established. Thrombocytopenia Thrombocytopenia &nbsp;has &nbsp;been reported &nbsp;in &nbsp;patients &nbsp;receiving &nbsp;filgrastim. &nbsp;Platelet counts &nbsp;should &nbsp;be monitored &nbsp;closely, &nbsp;especially &nbsp;during &nbsp;the first &nbsp;few &nbsp;weeks of &nbsp;filgrastim &nbsp;therapy. &nbsp;Consideration &nbsp;should be given &nbsp;to &nbsp;temporary &nbsp;discontinuation or &nbsp;dose &nbsp;reduction &nbsp;of &nbsp;filgrastim &nbsp;in &nbsp;patients &nbsp;with &nbsp;severe &nbsp;chronic neutropenia &nbsp;who &nbsp;develop thrombocytopenia &nbsp;(platelet &nbsp;count &nbsp;&lt; &nbsp;100 &nbsp; &nbsp;x &nbsp;109/l). Leukocytosis White &nbsp;blood &nbsp;cell &nbsp;counts &nbsp;of &nbsp;100 &nbsp;x &nbsp;109/l &nbsp;or &nbsp;greater &nbsp;have &nbsp;been &nbsp;observed &nbsp;in &nbsp;less &nbsp;than &nbsp;5% &nbsp;of &nbsp;cancer &nbsp;patients receiving &nbsp;filgrastim &nbsp;at &nbsp;doses above 0.3 &nbsp;MU/kg/day &nbsp;(3 &nbsp;&mu;g/kg/day). No undesirable &nbsp;effects &nbsp;directly attributable to &nbsp;this degree of &nbsp;leukocytosis have been &nbsp;reported. &nbsp;However, &nbsp;in &nbsp;view &nbsp;of &nbsp;the potential &nbsp;risks associated &nbsp;with &nbsp;severe leukocytosis, &nbsp;a &nbsp;white blood cell &nbsp;count &nbsp;should be &nbsp;performed at &nbsp;regular &nbsp;intervals during &nbsp;filgrastim &nbsp;therapy. If &nbsp;leukocyte &nbsp;counts &nbsp;exceed 50 &nbsp;x &nbsp;109/l &nbsp;after &nbsp;the &nbsp;expected &nbsp;nadir, filgrastim should be &nbsp;discontinued immediately. &nbsp;When administered &nbsp;for &nbsp;PBPC &nbsp;mobilisation, &nbsp;filgrastim &nbsp;should be discontinued or &nbsp;its &nbsp;dosage &nbsp;should be &nbsp;reduced if &nbsp;the &nbsp;leukocyte &nbsp;counts &nbsp;rise &nbsp;to &gt; &nbsp;70 &nbsp;x &nbsp;109/l. Immunogenicity As &nbsp;with &nbsp;all therapeutic &nbsp;proteins, &nbsp;there &nbsp;is &nbsp;a &nbsp;potential for &nbsp;immunogenicity. &nbsp;Rates &nbsp;of &nbsp;generation of antibodies &nbsp;against &nbsp;filgrastim &nbsp;is generally &nbsp;low. &nbsp;Binding &nbsp;antibodies &nbsp;do &nbsp;occur &nbsp;as expected &nbsp;with &nbsp;all biologics; &nbsp;however, &nbsp;they &nbsp;have &nbsp;not &nbsp;been &nbsp;associated with &nbsp;neutralising &nbsp;activity &nbsp;at &nbsp;present. Special &nbsp;warning &nbsp;and &nbsp;precautions associated &nbsp;with &nbsp;co-morbidities Special &nbsp;precautions &nbsp;in sickle cell &nbsp;trait &nbsp;and &nbsp;sickle &nbsp;cell &nbsp;disease Sickle cell &nbsp;crises, &nbsp;in &nbsp;some cases &nbsp;fatal, &nbsp;have been &nbsp;reported &nbsp;with &nbsp;the use of &nbsp;filgrastim &nbsp;in &nbsp;patients with sickle &nbsp;cell &nbsp;trait &nbsp;or &nbsp;sickle &nbsp;cell &nbsp;disease. &nbsp;Physicians should &nbsp;use caution &nbsp;when &nbsp;prescribing &nbsp;filgrastim &nbsp;in patients &nbsp;with &nbsp;sickle cell &nbsp;trait &nbsp;or &nbsp;sickle &nbsp;cell &nbsp;disease. Osteoporosis Monitoring &nbsp;of &nbsp;bone &nbsp;density &nbsp;may &nbsp;be &nbsp;indicated &nbsp;in patients &nbsp;with &nbsp;underlying &nbsp;osteoporotic &nbsp;bone &nbsp;diseases who undergo continuous &nbsp;therapy &nbsp;with filgrastim &nbsp;for &nbsp;more &nbsp;than &nbsp;6 &nbsp;months. Special &nbsp;precautions in &nbsp;cancer &nbsp;patients Filgrastim &nbsp;should not &nbsp;be &nbsp;used to &nbsp;increase &nbsp;the &nbsp;dose &nbsp;of &nbsp;cytotoxic &nbsp;chemotherapy &nbsp;beyond established dosage regimens. 7 &nbsp;Pg. 7 Summary of Product Characteristics</p><p>Risks &nbsp;associated &nbsp;with &nbsp;increased &nbsp;doses &nbsp;of &nbsp;chemotherapy Special &nbsp;caution &nbsp;should &nbsp;be used &nbsp;when &nbsp;treating &nbsp;patients &nbsp;with &nbsp;high-dose &nbsp;chemotherapy &nbsp;because &nbsp;improved tumour &nbsp;outcome &nbsp;has &nbsp;not &nbsp;been demonstrated &nbsp;and &nbsp;intensified &nbsp;doses &nbsp;of &nbsp;chemotherapeutic agents may lead &nbsp;to &nbsp;increased &nbsp;toxicities including &nbsp;cardiac, &nbsp;pulmonary, &nbsp;neurologic, &nbsp;and &nbsp;dermatologic &nbsp;effects (please refer &nbsp;to &nbsp;the &nbsp;prescribing &nbsp;information &nbsp;of &nbsp;the specific chemotherapy &nbsp;agents &nbsp;used). Effect &nbsp;of &nbsp;chemotherapy on &nbsp;erythrocytes and &nbsp;thrombocytes Treatment &nbsp;with &nbsp;filgrastim &nbsp;alone &nbsp;does &nbsp;not &nbsp;preclude &nbsp;thrombocytopenia &nbsp;and &nbsp;anaemia &nbsp;due &nbsp;to myelosuppressive chemotherapy. &nbsp;Because of &nbsp;the potential &nbsp;of &nbsp;receiving &nbsp;higher &nbsp;doses of &nbsp;chemotherapy (e.g. full &nbsp;doses &nbsp;on the &nbsp;prescribed schedule) &nbsp;the &nbsp;patient &nbsp;may &nbsp;be &nbsp;at &nbsp;greater &nbsp;risk &nbsp;of &nbsp;thrombocytopenia &nbsp;and anaemia. Regular &nbsp;monitoring &nbsp;of &nbsp;platelet &nbsp;count &nbsp;and &nbsp;haematocrit &nbsp;is &nbsp;recommended. Special &nbsp;care &nbsp;should be &nbsp;taken when administering &nbsp;single &nbsp;or &nbsp;combination chemotherapeutic &nbsp;agents &nbsp;which are &nbsp;known to cause &nbsp;severe thrombocytopenia. The &nbsp;use of &nbsp;filgrastim-mobilised PBPCs &nbsp;has &nbsp;been &nbsp;shown to reduce &nbsp;the &nbsp;depth &nbsp;and duration &nbsp;of thrombocytopenia &nbsp;following &nbsp;myelosuppressive &nbsp;or &nbsp;myeloablative &nbsp;chemotherapy. Other special precautions The &nbsp;effects &nbsp;of &nbsp;filgrastim &nbsp;in patients &nbsp;with substantially &nbsp;reduced &nbsp;myeloid progenitors &nbsp;have &nbsp;not &nbsp;been studied. Filgrastim &nbsp;acts &nbsp;primarily &nbsp;on neutrophil &nbsp;precursors &nbsp;to exert &nbsp;its &nbsp;effect &nbsp;in elevating &nbsp;neutrophil counts. Therefore, &nbsp;in patients &nbsp;with &nbsp;reduced precursors, &nbsp;neutrophil &nbsp;response &nbsp;may &nbsp;be &nbsp;diminished (such as &nbsp;those &nbsp;treated with extensive &nbsp;radiotherapy &nbsp;or &nbsp;chemotherapy, or &nbsp;those &nbsp;with bone &nbsp;marrow &nbsp;infiltration by &nbsp;tumour). Vascular &nbsp;disorders, &nbsp;including &nbsp;veno-occlusive &nbsp;disease &nbsp;and fluid volume &nbsp;disturbances, &nbsp;have been reported occasionally &nbsp;in patients &nbsp;undergoing &nbsp;high dose &nbsp;chemotherapy &nbsp;followed by &nbsp;transplantation. There have &nbsp;been &nbsp;reports &nbsp;of &nbsp;Graft &nbsp;versus &nbsp;Host &nbsp;Disease &nbsp;(GvHD) &nbsp;and &nbsp;fatalities &nbsp;in &nbsp;patients &nbsp;receiving G-CSF &nbsp;after &nbsp;allogeneic bone marrow &nbsp;transplantation &nbsp;(see section &nbsp;4.8 and 5.1). Increased haematopoietic &nbsp;activity &nbsp;of &nbsp;the &nbsp;bone &nbsp;marrow &nbsp;in response &nbsp;to growth &nbsp;factor &nbsp;therapy &nbsp;has &nbsp;been associated &nbsp;with &nbsp;transient &nbsp;abnormal &nbsp;bone &nbsp;scans. &nbsp;This should &nbsp;be considered &nbsp;when &nbsp;interpreting &nbsp;boneimaging &nbsp;results. Aortitis &nbsp;has &nbsp;been reported &nbsp;after &nbsp;G-CSF &nbsp;administration &nbsp;in &nbsp;healthy &nbsp;subjects &nbsp;and &nbsp;in &nbsp;cancer &nbsp;patients. &nbsp;The symptoms &nbsp;experienced &nbsp;included fever, abdominal &nbsp;pain, malaise, back &nbsp;pain and &nbsp;inflammatory &nbsp;markers (e.g. C-reactive protein &nbsp;and &nbsp;white &nbsp;blood &nbsp;cell &nbsp;count) &nbsp;were raised. &nbsp;In &nbsp;most &nbsp;cases &nbsp;aortitis was &nbsp;diagnosed by &nbsp;CT &nbsp;scan &nbsp;and &nbsp;generally &nbsp;resolved &nbsp;after &nbsp;withdrawal &nbsp;of &nbsp;G-CSF. &nbsp;See also &nbsp;section &nbsp;4.8. Special &nbsp;precautions &nbsp;in &nbsp;patients &nbsp;undergoing &nbsp;PBPC &nbsp;mobilisation Mobilisation There &nbsp;are &nbsp;no prospectively &nbsp;randomised &nbsp;comparisons &nbsp;of &nbsp;the &nbsp;two recommended mobilisation methods (Filgrastim &nbsp;alone, or &nbsp;in combination with myelosuppressive &nbsp;chemotherapy) &nbsp;within the &nbsp;same &nbsp;patient population. &nbsp;The &nbsp;degree &nbsp;of &nbsp;variation between individual &nbsp;patients &nbsp;and between &nbsp;laboratory &nbsp;assays &nbsp;of CD34+ &nbsp;cells mean &nbsp;that &nbsp;direct &nbsp;comparison &nbsp;between &nbsp;different &nbsp;studies &nbsp;is difficult. &nbsp;It &nbsp;is therefore difficult to recommend an optimum &nbsp;method. The &nbsp;choice &nbsp;of &nbsp;mobilisation &nbsp;method &nbsp;should be &nbsp;considered in relation &nbsp;to &nbsp;the &nbsp;overall &nbsp;objectives &nbsp;of &nbsp;treatment for &nbsp;an &nbsp;individual &nbsp;patient.</p><p>Prior exposure &nbsp;to &nbsp;cytotoxic agents Patients who &nbsp;have undergone very &nbsp;extensive prior &nbsp;myelosuppressive &nbsp;therapy &nbsp;may &nbsp;not &nbsp;show &nbsp;sufficient mobilisation of &nbsp;PBPC &nbsp;to achieve &nbsp;the &nbsp;recommended minimum &nbsp;yield &nbsp;(&ge; &nbsp;2.0 &nbsp;x &nbsp;106 &nbsp;CD34+ &nbsp;cells/kg) &nbsp;or acceleration &nbsp;of &nbsp;platelet &nbsp;recovery &nbsp;to &nbsp;the same degree. Some &nbsp;cytotoxic &nbsp;agents &nbsp;exhibit &nbsp;particular &nbsp;toxicities &nbsp;to the &nbsp;haematopoietic &nbsp;progenitor &nbsp;pool &nbsp;and may adversely &nbsp;affect &nbsp;progenitor &nbsp;mobilisation. Agents &nbsp;such &nbsp;as &nbsp;melphalan, carmustine &nbsp;(BCNU) &nbsp;and carboplatin, when &nbsp;administered &nbsp;over &nbsp;prolonged periods &nbsp;prior &nbsp;to attempts &nbsp;at &nbsp;progenitor &nbsp;mobilisation may &nbsp;reduce &nbsp;progenitor &nbsp;yield. However, the &nbsp;administration of &nbsp;melphalan, carboplatin &nbsp;or &nbsp;BCNU together &nbsp;with filgrastim &nbsp;has &nbsp;been shown to &nbsp;be &nbsp;effective &nbsp;for &nbsp;progenitor &nbsp;mobilisation. When &nbsp;a &nbsp;PBPC transplantation &nbsp;is &nbsp;envisaged &nbsp;it &nbsp;is advisable &nbsp;to &nbsp;plan &nbsp;the stem &nbsp;cell &nbsp;mobilisation &nbsp;procedure early &nbsp;in &nbsp;the treatment course &nbsp;of &nbsp;the &nbsp;patient. &nbsp;Particular &nbsp;attention &nbsp;should be &nbsp;paid to &nbsp;the &nbsp;number &nbsp;of &nbsp;progenitors mobilised in such &nbsp;patients &nbsp;before &nbsp;the &nbsp;administration &nbsp;of &nbsp;high-dose chemotherapy. &nbsp;If &nbsp;yields are inadequate, as &nbsp;measured by &nbsp;the &nbsp;criteria &nbsp;above, alternative &nbsp;forms &nbsp;of &nbsp;treatment &nbsp;not &nbsp;requiring &nbsp;progenitor support &nbsp;should be &nbsp;considered. Assessment &nbsp;of &nbsp;progenitor &nbsp;cell &nbsp;yields In &nbsp;assessing &nbsp;the number &nbsp;of &nbsp;progenitor &nbsp;cells harvested &nbsp;in &nbsp;patients &nbsp;treated &nbsp;with &nbsp;filgrastim, &nbsp;particular attention &nbsp;should be &nbsp;paid to &nbsp;the &nbsp;method of &nbsp;quantitation. &nbsp;The &nbsp;results &nbsp;of &nbsp;flow &nbsp;cytometric &nbsp;analysis &nbsp;of CD34+ &nbsp;cell &nbsp;numbers &nbsp;vary &nbsp;depending &nbsp;on the &nbsp;precise &nbsp;methodology &nbsp;used and, recommendations &nbsp;of numbers &nbsp;based on studies &nbsp;in other &nbsp;laboratories &nbsp;need &nbsp;to &nbsp;be &nbsp;interpreted with caution. Statistical &nbsp;analysis &nbsp;of &nbsp;the relationship &nbsp;between &nbsp;the &nbsp;number &nbsp;of &nbsp;CD34+ &nbsp;cells re-infused &nbsp;and the &nbsp;rate &nbsp;of platelet &nbsp;recovery &nbsp;after &nbsp;high-dose &nbsp;chemotherapy &nbsp;indicates &nbsp;a &nbsp;complex but &nbsp;continuous &nbsp;relationship. The &nbsp;recommendation &nbsp;of &nbsp;a &nbsp;minimum &nbsp;yield of &nbsp;&ge; &nbsp;2.0 &nbsp;x &nbsp;106 &nbsp;CD34+ &nbsp;cells/kg &nbsp;is &nbsp;based &nbsp;on published experience &nbsp;resulting &nbsp;in &nbsp;adequate &nbsp;haematologic reconstitution. &nbsp;Yields &nbsp;in &nbsp;excess of &nbsp;this &nbsp;appear &nbsp;to correlate with &nbsp;more rapid &nbsp;recovery, &nbsp;those below &nbsp;with &nbsp;slower &nbsp;recovery. Special &nbsp;precautions in &nbsp;normal &nbsp;donors &nbsp;undergoing &nbsp;PBPC &nbsp;mobilisation Mobilisation &nbsp;of &nbsp;PBPC &nbsp;does &nbsp;not &nbsp;provide &nbsp;a &nbsp;direct &nbsp;clinical &nbsp;benefit &nbsp;to normal &nbsp;donors &nbsp;and should only &nbsp;be considered for &nbsp;the &nbsp;purposes &nbsp;of &nbsp;allogeneic &nbsp;stem &nbsp;cell &nbsp;transplantation. PBPC mobilisation &nbsp;should &nbsp;be &nbsp;considered &nbsp;only &nbsp;in &nbsp;donors &nbsp;who meet &nbsp;normal &nbsp;clinical &nbsp;and laboratory eligibility &nbsp;criteria &nbsp;for &nbsp;stem &nbsp;cell donation &nbsp;with &nbsp;special attention &nbsp;to &nbsp;haematological &nbsp;values &nbsp;and &nbsp;infectious disease. The &nbsp;safety &nbsp;and &nbsp;efficacy &nbsp;of &nbsp;filgrastim &nbsp;have not &nbsp;been &nbsp;assessed &nbsp;in &nbsp;normal &nbsp;donors &nbsp;&lt; &nbsp;16 &nbsp;years or &nbsp;&gt; &nbsp;60 &nbsp;years. Transient &nbsp;thrombocytopenia (platelets &nbsp;&lt; &nbsp;100 &nbsp;x &nbsp;109/l) &nbsp;following &nbsp;filgrastim &nbsp;administration and leukapheresis was observed &nbsp;in &nbsp;35% &nbsp;of &nbsp;subjects &nbsp;studied. &nbsp;Among &nbsp;these, &nbsp;two &nbsp;cases of &nbsp;platelets &lt; &nbsp;50 &nbsp;x 109/l &nbsp;were &nbsp;reported &nbsp;and &nbsp;attributed to &nbsp;the &nbsp;leukapheresis &nbsp;procedure. If &nbsp;more &nbsp;than one &nbsp;leukapheresis &nbsp;is &nbsp;required, particular &nbsp;attention should be &nbsp;paid &nbsp;to donors &nbsp;with platelets &nbsp;&lt; &nbsp;100 &nbsp;x &nbsp;109/l &nbsp;prior &nbsp;to leukapheresis; &nbsp;in general &nbsp;apheresis &nbsp;should not &nbsp;be &nbsp;performed if platelets &nbsp;&lt; &nbsp;75 &nbsp;x &nbsp;109/l. Leukapheresis &nbsp;should not &nbsp;be &nbsp;performed in &nbsp;donors &nbsp;who &nbsp;are &nbsp;anticoagulated or &nbsp;who have &nbsp;known defects in &nbsp;haemostasis. Donors &nbsp;who &nbsp;receive &nbsp;G-CSFs &nbsp;for &nbsp;PBPC &nbsp;mobilisation should be &nbsp;monitored until &nbsp;haematological &nbsp;indices return to &nbsp;normal.&nbsp;</p><p>Transient &nbsp;cytogenetic &nbsp;abnormalities have been &nbsp;observed in normal &nbsp;donors &nbsp;following &nbsp;G-CSF &nbsp;use. The significance of &nbsp;these changes is unknown. &nbsp;Nevertheless, &nbsp;a risk &nbsp;of &nbsp;promotion &nbsp;of &nbsp;a &nbsp;malignant &nbsp;myeloid clone &nbsp;cannot &nbsp;be excluded. &nbsp;It &nbsp;is &nbsp;recommended &nbsp;that &nbsp;the apheresis centre perform &nbsp;a systematic record &nbsp;and tracking &nbsp;of &nbsp;the &nbsp;stem &nbsp;cell &nbsp;donors &nbsp;for &nbsp;at &nbsp;least &nbsp;10 &nbsp;years &nbsp;to ensure &nbsp;monitoring &nbsp;of &nbsp;long-term &nbsp;safety. Special &nbsp;precautions in &nbsp;recipients &nbsp;of &nbsp;allogeneic &nbsp;PBPCs &nbsp;mobilised &nbsp;with &nbsp;filgrastim Current &nbsp;data &nbsp;indicate &nbsp;that &nbsp;immunological interactions &nbsp;between &nbsp;the &nbsp;allogeneic &nbsp;PBPC &nbsp;graft and &nbsp;the recipient &nbsp;may &nbsp;be associated &nbsp;with &nbsp;an &nbsp;increased &nbsp;risk &nbsp;of &nbsp;acute &nbsp;and &nbsp;chronic GvHD &nbsp;when &nbsp;compared &nbsp;with bone &nbsp;marrow &nbsp;transplantation. Special &nbsp;precautions in &nbsp;SCN &nbsp;patients Filgrastim &nbsp;should not &nbsp;be &nbsp;administered &nbsp;to patients &nbsp;with &nbsp;severe &nbsp;congenital &nbsp;neutropenia &nbsp;who develop leukaemia or &nbsp;have evidence &nbsp;of &nbsp;leukaemic evolution. Blood cell &nbsp;counts Other &nbsp;blood cell &nbsp;changes &nbsp;occur, &nbsp;including &nbsp;anaemia &nbsp;and &nbsp;transient &nbsp;increases &nbsp;in myeloid progenitors, which &nbsp;require &nbsp;close &nbsp;monitoring &nbsp;of &nbsp;cell &nbsp;counts. Transformation &nbsp;to &nbsp;leukaemia or &nbsp;myelodysplastic &nbsp;syndrome Special &nbsp;care should &nbsp;be taken &nbsp;in &nbsp;the diagnosis &nbsp;of &nbsp;SCNs &nbsp;to distinguish &nbsp;them &nbsp;from &nbsp;other &nbsp;haematopoietic disorders such &nbsp;as aplastic anaemia, &nbsp;myelodysplasia, &nbsp;and &nbsp;myeloid &nbsp;leukaemia. &nbsp;Complete blood &nbsp;cell counts &nbsp;with differential &nbsp;and &nbsp;platelet &nbsp;counts, &nbsp;and an &nbsp;evaluation of &nbsp;bone &nbsp;marrow &nbsp;morphology &nbsp;and karyotype &nbsp;should be &nbsp;performed prior &nbsp;to treatment. There &nbsp;was &nbsp;a &nbsp;low &nbsp;frequency &nbsp;(approximately &nbsp;3%) &nbsp;of &nbsp;myelodysplastic &nbsp;syndromes &nbsp;(MDS) &nbsp;or &nbsp;leukaemia &nbsp;in clinical &nbsp;trial patients &nbsp;with &nbsp;SCN &nbsp;treated &nbsp;with &nbsp;filgrastim. &nbsp;This &nbsp;observation &nbsp;has &nbsp;only &nbsp;been &nbsp;made &nbsp;in patients &nbsp;with congenital &nbsp;neutropenia. &nbsp;MDS &nbsp;and &nbsp;leukaemias are natural &nbsp;complications of &nbsp;the &nbsp;disease and are &nbsp;of &nbsp;uncertain relation to filgrastim &nbsp;therapy. A &nbsp;subset &nbsp;of &nbsp;approximately &nbsp;12% &nbsp;of &nbsp;patients &nbsp;who &nbsp;had normal &nbsp;cytogenetic evaluations at &nbsp;baseline was subsequently &nbsp;found &nbsp;to &nbsp;have abnormalities, including monosomy &nbsp;7, on routine &nbsp;repeat &nbsp;evaluation. It &nbsp;is &nbsp;currently &nbsp;unclear &nbsp;whether &nbsp;long-term &nbsp;treatment &nbsp;of patients with &nbsp;SCN &nbsp;will &nbsp;predispose patients &nbsp;to &nbsp;cytogenetic abnormalities, &nbsp;MDS &nbsp;or &nbsp;leukaemic transformation. It &nbsp;is &nbsp;recommended to perform &nbsp;morphologic &nbsp;and cytogenetic &nbsp;bone &nbsp;marrow examinations &nbsp;in &nbsp;patients at &nbsp;regular &nbsp;intervals (approximately &nbsp;every &nbsp;12 &nbsp;months). Other special &nbsp;precautions Causes &nbsp;of &nbsp;transient &nbsp;neutropenia, &nbsp;such &nbsp;as viral &nbsp;infections should &nbsp;be &nbsp;excluded. Haematuria &nbsp;was common &nbsp;and &nbsp;proteinuria occurred &nbsp;in &nbsp;a &nbsp;small &nbsp;number &nbsp;of &nbsp;patients. &nbsp;Regular &nbsp;urinalysis should be &nbsp;performed to monitor &nbsp;these &nbsp;events. The &nbsp;safety &nbsp;and &nbsp;efficacy &nbsp;in &nbsp;neonates &nbsp;and &nbsp;patients &nbsp;with autoimmune &nbsp;neutropenia &nbsp;have &nbsp;not &nbsp;been established. Special precautions &nbsp;in &nbsp;patients &nbsp;with &nbsp;HIV &nbsp;infection Blood cell &nbsp;counts Absolute &nbsp;neutrophil &nbsp;count &nbsp;(ANC) &nbsp;should be &nbsp;monitored &nbsp;closely, especially &nbsp;during &nbsp;the &nbsp;first &nbsp;few &nbsp;weeks of &nbsp;filgrastim &nbsp;therapy. Some &nbsp;patients may &nbsp;respond &nbsp;very &nbsp;rapidly &nbsp;and &nbsp;with &nbsp;a considerable &nbsp;increase &nbsp;in neutrophil &nbsp;count &nbsp;to &nbsp;the &nbsp;initial &nbsp;dose &nbsp;of &nbsp;filgrastim. &nbsp;It &nbsp;is &nbsp;recommended that &nbsp;the &nbsp;ANC &nbsp;is &nbsp;measured daily &nbsp;for the first &nbsp;2 &nbsp;- &nbsp;3 &nbsp;days &nbsp;of &nbsp;filgrastim &nbsp;administration. &nbsp;Thereafter, &nbsp;it &nbsp;is &nbsp;recommended that &nbsp;the &nbsp;ANC &nbsp;is measured &nbsp;at &nbsp;least &nbsp;twice &nbsp;per &nbsp;week &nbsp;for &nbsp;the first &nbsp;2 &nbsp;weeks and &nbsp;subsequently &nbsp;once per &nbsp;week &nbsp;or &nbsp;once every&nbsp;other &nbsp;week &nbsp;during &nbsp;maintenance &nbsp;therapy. During &nbsp;intermittent &nbsp;dosing &nbsp;with 30 &nbsp;MU/day &nbsp;(300 &nbsp;&mu;g/day) &nbsp;of filgrastim, there &nbsp;can &nbsp;be &nbsp;wide &nbsp;fluctuations &nbsp;in &nbsp;the &nbsp;patient&#39;s &nbsp;ANC &nbsp;over &nbsp;time. In order &nbsp;to determine &nbsp;a patient&#39;s &nbsp;trough or &nbsp;nadir &nbsp;ANC, it &nbsp;is &nbsp;recommended that &nbsp;blood &nbsp;samples &nbsp;are &nbsp;taken for &nbsp;ANC &nbsp;measurement immediately &nbsp;prior &nbsp;to &nbsp;any &nbsp;scheduled &nbsp;dosing &nbsp;with &nbsp;filgrastim. Risk associated &nbsp;with &nbsp;increased &nbsp;doses of &nbsp;myelosuppressive medicinal &nbsp;products Treatment with &nbsp;filgrastim &nbsp;alone &nbsp;does &nbsp;not &nbsp;preclude &nbsp;thrombocytopenia &nbsp;and &nbsp;anaemia &nbsp;due &nbsp;to myelosuppressive treatments. &nbsp;As &nbsp;a result &nbsp;of &nbsp;the potential &nbsp;to &nbsp;receive higher &nbsp;doses &nbsp;or &nbsp;a greater &nbsp;number of &nbsp;these &nbsp;medicinal &nbsp;products &nbsp;with &nbsp;filgrastim &nbsp;therapy, the &nbsp;patient &nbsp;may &nbsp;be &nbsp;at &nbsp;higher &nbsp;risk &nbsp;of &nbsp;developing thrombocytopenia &nbsp;and anaemia. Regular &nbsp;monitoring &nbsp;of &nbsp;blood &nbsp;counts &nbsp;is &nbsp;recommended (see &nbsp;above). Infections &nbsp;and malignancies &nbsp;causing myelosuppression Neutropenia &nbsp;may &nbsp;be &nbsp;due &nbsp;to &nbsp;bone &nbsp;marrow-infiltrating &nbsp;opportunistic &nbsp;infections &nbsp;such &nbsp;as &nbsp;Mycobacterium avium &nbsp;complex or &nbsp;malignancies &nbsp;such as &nbsp;lymphoma. &nbsp;In &nbsp;patients &nbsp;with known bone &nbsp;marrow &nbsp;infiltrating infections &nbsp;or &nbsp;malignancy, consider &nbsp;appropriate &nbsp;therapy &nbsp;for &nbsp;treatment &nbsp;of &nbsp;the &nbsp;underlying &nbsp;condition in addition &nbsp;to &nbsp;administration &nbsp;of &nbsp;filgrastim &nbsp;for &nbsp;treatment of &nbsp;neutropenia. &nbsp;The effects of &nbsp;filgrastim &nbsp;on neutropenia &nbsp;due &nbsp;to &nbsp;bone &nbsp;marrow-infiltrating &nbsp;infection &nbsp;or &nbsp;malignancy &nbsp;have not &nbsp;been &nbsp;well &nbsp;established. All patients Latex-sensitive &nbsp;individuals The &nbsp;removable &nbsp;needle &nbsp;cap &nbsp;of &nbsp;this &nbsp;pre-filled &nbsp;syringe &nbsp;contains &nbsp;a &nbsp;derivative &nbsp;of &nbsp;natural &nbsp;rubber &nbsp;latex. No natural &nbsp;rubber &nbsp;latex &nbsp;has to &nbsp;date been &nbsp;detected &nbsp;in &nbsp;the &nbsp;removable &nbsp;needle cap. &nbsp;Nevertheless, &nbsp;the &nbsp;use &nbsp;of Zarzio solution for &nbsp;injection &nbsp;in &nbsp;pre-filled &nbsp;syringe in &nbsp;latex-sensitive &nbsp;individuals &nbsp;has &nbsp;not &nbsp;been studied and &nbsp;thus &nbsp;there is a potential &nbsp;risk &nbsp;for &nbsp;hypersensitivity &nbsp;reactions which &nbsp;cannot &nbsp;be completely &nbsp;ruled &nbsp;out. Excipients Zarzio &nbsp;contains &nbsp;sorbitol &nbsp;(E420). &nbsp;Patients &nbsp;with hereditary &nbsp;fructose &nbsp;intolerance &nbsp;(HFI) &nbsp;must &nbsp;not &nbsp;be &nbsp;given this medicine unless strictly &nbsp;necessary. Babies &nbsp;and young &nbsp;children &nbsp;(below &nbsp;2 years &nbsp;of &nbsp;age) &nbsp;may &nbsp;not &nbsp;yet &nbsp;be &nbsp;diagnosed &nbsp;with &nbsp;hereditary &nbsp;fructose intolerance &nbsp;(HFI). Medicines &nbsp;(containing &nbsp;sorbitol/fructose) &nbsp;given &nbsp;intravenously may be &nbsp;lifethreatening &nbsp;and &nbsp;should be &nbsp;contraindicated in &nbsp;this &nbsp;population unless &nbsp;there &nbsp;is &nbsp;an overwhelming &nbsp;clinical need &nbsp;and &nbsp;no &nbsp;alternatives are &nbsp;available. A detailed history &nbsp;with &nbsp;regard to HFI &nbsp;symptoms &nbsp;has to &nbsp;be taken &nbsp;of &nbsp;each &nbsp;patient &nbsp;prior &nbsp;to being &nbsp;given this medicinal &nbsp;product. In order &nbsp;to &nbsp;improve &nbsp;the &nbsp;traceability &nbsp;of &nbsp;granulocyte-colony &nbsp;stimulating &nbsp;factors &nbsp;(G-CSFs), the &nbsp;trade name &nbsp;of &nbsp;the &nbsp;administered product &nbsp;should &nbsp;be &nbsp;clearly &nbsp;recorded &nbsp;in &nbsp;the &nbsp;patient &nbsp;file.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The &nbsp;safety &nbsp;and &nbsp;efficacy &nbsp;of &nbsp;filgrastim &nbsp;given &nbsp;on &nbsp;the same day &nbsp;as myelosuppressive cytotoxic chemotherapy &nbsp;have &nbsp;not &nbsp;been definitively &nbsp;established. &nbsp;In view &nbsp;of &nbsp;the &nbsp;sensitivity &nbsp;of &nbsp;rapidly &nbsp;dividing myeloid cells &nbsp;to myelosuppressive &nbsp;cytotoxic &nbsp;chemotherapy, the &nbsp;use &nbsp;of &nbsp;filgrastim &nbsp;is &nbsp;not &nbsp;recommended in the &nbsp;period from &nbsp;24 &nbsp;hours &nbsp;before &nbsp;to 24 &nbsp;hours &nbsp;after &nbsp;chemotherapy. Preliminary &nbsp;evidence from &nbsp;a small number &nbsp;of &nbsp;patients &nbsp;treated &nbsp;concomitantly &nbsp;with &nbsp;filgrastim &nbsp;and 5-fluorouracil indicates &nbsp;that &nbsp;the &nbsp;severity of &nbsp;neutropenia may &nbsp;be exacerbated. Possible &nbsp;interactions with &nbsp;other &nbsp;haematopoietic growth &nbsp;factors and &nbsp;cytokines have not &nbsp;yet &nbsp;been investigated &nbsp;in &nbsp;clinical trials.&nbsp;</p><p>Since &nbsp;lithium &nbsp;promotes &nbsp;the &nbsp;release &nbsp;of &nbsp;neutrophils, &nbsp;lithium &nbsp;is &nbsp;likely &nbsp;to &nbsp;potentiate &nbsp;the &nbsp;effect of &nbsp;filgrastim. Although this &nbsp;interaction &nbsp;has &nbsp;not &nbsp;been formally &nbsp;investigated, there &nbsp;is &nbsp;no evidence &nbsp;that &nbsp;such an interaction is &nbsp;harmful.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy There &nbsp;are &nbsp;no or &nbsp;limited amount &nbsp;of &nbsp;data &nbsp;from &nbsp;the &nbsp;use &nbsp;of &nbsp;filgrastim &nbsp;in pregnant &nbsp;women. Studies &nbsp;in animals &nbsp;have &nbsp;shown reproductive &nbsp;toxicity. An increased incidence &nbsp;of &nbsp;embryo-loss &nbsp;has been &nbsp;observed in &nbsp;rabbits &nbsp;at &nbsp;high &nbsp;multiples &nbsp;of &nbsp;the clinical &nbsp;exposure &nbsp;and &nbsp;in &nbsp;the presence &nbsp;of &nbsp;maternal &nbsp;toxicity &nbsp;(see section &nbsp;5.3). &nbsp;There are reports &nbsp;in &nbsp;the &nbsp;literature &nbsp;where the transplacental &nbsp;passage of &nbsp;filgrastim &nbsp;in pregnant &nbsp;women &nbsp;has &nbsp;been demonstrated. Zarzio is &nbsp;not &nbsp;recommended during &nbsp;pregnancy. Breast-feeding It &nbsp;is &nbsp;unknown whether &nbsp;filgrastim/metabolites &nbsp;are &nbsp;excreted &nbsp;in human milk. A &nbsp;risk &nbsp;to the newborns/infants &nbsp;cannot &nbsp;be &nbsp;excluded. A &nbsp;decision must &nbsp;be &nbsp;made &nbsp;whether &nbsp;to discontinue &nbsp;breast-feeding or &nbsp;to discontinue/abstain from &nbsp;Zarzio therapy &nbsp;taking &nbsp;into account &nbsp;the &nbsp;benefit &nbsp;of &nbsp;breast &nbsp;feeding &nbsp;for &nbsp;the child and &nbsp;the &nbsp;benefit &nbsp;of &nbsp;therapy &nbsp;for &nbsp;the &nbsp;woman. Fertility Filgrastim &nbsp;did &nbsp;not &nbsp;affect &nbsp;reproductive performance or &nbsp;fertility &nbsp;in &nbsp;male or &nbsp;female &nbsp;rats &nbsp;(see section &nbsp;5.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim &nbsp;may &nbsp;have a minor &nbsp;influence on &nbsp;the &nbsp;ability &nbsp;to &nbsp;drive and &nbsp;use &nbsp;machines. &nbsp;Dizziness may &nbsp;occur following &nbsp;the &nbsp;administration of &nbsp;filgrastim &nbsp;(see &nbsp;section &nbsp;4.8).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary &nbsp;of &nbsp;the &nbsp;safety &nbsp;profile</u></p><p>The &nbsp;most &nbsp;serious adverse reactions &nbsp;that &nbsp;may &nbsp;occur &nbsp;during &nbsp;filgrastim &nbsp;treatment &nbsp;include: &nbsp;anaphylactic reaction, &nbsp;serious pulmonary &nbsp;adverse &nbsp;events &nbsp;(including &nbsp;interstitial &nbsp;pneumonia &nbsp;and ARDS), capillary leak &nbsp;syndrome, severe &nbsp;splenomegaly/splenic &nbsp;rupture, transformation to myelodysplastic &nbsp;syndrome &nbsp;or leukaemia in &nbsp;SCN &nbsp;patients, &nbsp;GvHD &nbsp;in &nbsp;patients &nbsp;receiving &nbsp;allogeneic bone &nbsp;marrow &nbsp;transfer &nbsp;or &nbsp;peripheral blood cell &nbsp;progenitor &nbsp;cell &nbsp;transplant &nbsp;and &nbsp;sickle &nbsp;cell &nbsp;crisis in &nbsp;patients with &nbsp;sickle cell &nbsp;disease. The &nbsp;most &nbsp;commonly &nbsp;reported adverse &nbsp;reactions &nbsp;are &nbsp;pyrexia, musculoskeletal &nbsp;pain &nbsp;(which &nbsp;includes bone &nbsp;pain, back &nbsp;pain, &nbsp;arthralgia, myalgia, pain in extremity, &nbsp;musculoskeletal &nbsp;pain, &nbsp;musculoskeletal chest &nbsp;pain, &nbsp;neck &nbsp;pain), &nbsp;anaemia, &nbsp;vomiting, &nbsp;and &nbsp;nausea. &nbsp;In &nbsp;clinical &nbsp;trials in &nbsp;cancer &nbsp;patients musculoskeletal &nbsp;pain was &nbsp;mild or &nbsp;moderate &nbsp;in &nbsp;10%, and severe &nbsp;in 3% &nbsp;of &nbsp;patients.</p><p><u>b. Tabulated &nbsp;summary &nbsp;of &nbsp;adverse &nbsp;reactions </u></p><p>The &nbsp;data in &nbsp;the tables below &nbsp;describe &nbsp;adverse reactions reported &nbsp;from &nbsp;clinical &nbsp;trials and &nbsp;spontaneous reporting. Within each frequency &nbsp;grouping, undesirable effects &nbsp;are &nbsp;presented &nbsp;in &nbsp;order &nbsp;of &nbsp;decreasing seriousness. &nbsp;&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis Bronchitis</p><p>Upper respiratory tract infection Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Thrombocyto- penia Anaemiae</p></td><td style="vertical-align:top"><p>Splenomegalya Haemoglobin decreasede</p></td><td style="vertical-align:top"><p>Leukocytosisa</p></td><td style="vertical-align:top"><p>Splenic rupturea Sickle cell anaemia with crisis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune sys- tem disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity Drug hypersensitivitya Graft versus host diseaseb</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased Appetitee Blood lactate dehydrogenase increased</p></td><td style="vertical-align:top"><p>Hyperuricaemia Blood uric acid increased</p></td><td style="vertical-align:top"><p>Blood glucose decreased Pseudogouta (Chondrocal- cinosis Pyro- phosphate) Fluid volume disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headachea</p></td><td style="vertical-align:top"><p>Dizziness Hypoaesthesia Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension Hypotension</p></td><td style="vertical-align:top"><p>Veno-occlusive diseased</p></td><td style="vertical-align:top"><p>Aortitis Capillary leak syndromea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemoptysis Dyspnoea Cougha Oropharyngeal paina, e Epistaxis</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndromea Respiratory failurea Pulmonary oedemaa Pulmonary haemorrhage Interstitial lung diseasea</p><p>Lung infiltrationa Hypoxia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointesti- nal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoeaa, e Vomitinga, e Nauseaa</p></td><td style="vertical-align:top"><p>Oral pain Constipatione</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatomegaly Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Aspartate ami- notransferase increased Gamma- glutamyl transferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Alopeciaa</p></td><td style="vertical-align:top"><p>Rasha Erythema</p></td><td style="vertical-align:top"><p>Maculopapular rash</p></td><td style="vertical-align:top"><p>Cutaneous vasculitisa Sweets syndrome (acute febrile neutrophilic dermatosis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskele- tal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Musculoskele- tal painc</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>Bone density decreased Exacerbation of rheumatoid arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria Haematuria</p></td><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Glomerulo- nephritis Urine abnormality</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administra- tion site conditions</strong></p></td><td style="vertical-align:top"><p>Fatiguea Mucosal inflammationa Pyrexia</p></td><td style="vertical-align:top"><p>Chest paina Paina Astheniaa Malaisee Oedema peripherale</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common (&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge; 1/100 to</strong></p><p><strong>&lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to</strong></p><p><strong>&lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt; 1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>See section c (Description of selected adverse reactions)</p><p>b There have been reports of GvHD and fatalities in patients after allogeneic bone marrow transplantation (see section c)</p><p>c Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain</p><p>d Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or</p><p>PBPC mobilisation</p><p>e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy</p><p>&nbsp;</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p><em>&nbsp;</em></p><p>Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.</p><p>&nbsp;</p><p><em>Pulmonary adverse events</em></p><p><em>&nbsp;</em></p><p>In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Splenomegaly and Splenic rupture</em></p><p><em>&nbsp;</em></p><p>Cases of splenomegaly and splenic rupture have been reported following administration of filgrastim. Some cases of splenic rupture were fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Capillary leak syndrome</em></p><p><em>&nbsp;</em></p><p>Cases of capillary leak syndrome have been reported with granulocyte colony-stimulating factor use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).</p><p>&nbsp;</p><p><em>Cutaneous vasculitis</em></p><p><em>&nbsp;</em></p><p>Cutaneous vasculitis has been reported in patients treated with filgrastim. The mechanism of vasculitis in patients receiving filgrastim is unknown. During long term use cutaneous vasculitis has been reported in 2% of SCN patients.</p><p>&nbsp;</p><p><em>Leukocytosis</em></p><p><em>&nbsp;</em></p><p>Leukocytosis (WBC &gt; 50 x 109/l) was observed in 41% of normal donors and transient thrombocytopenia (platelets &lt; 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).</p>&nbsp;<p><em>Sweets syndrome</em></p><p><em>&nbsp;</em></p><p>Cases of Sweets syndrome (acute febrile neutrophilic dermatosis) have been reported in patients treated with filgrastim.</p><p>&nbsp;</p><p><em>Pseudogout (chondrocalcinosis pyrophosphate)</em></p><p><em>&nbsp;</em></p><p>Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim.</p><p>&nbsp;</p><p><em>GvHD</em></p><p><em>&nbsp;</em></p><p>There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.4 and 5.1).</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u></p><p>&nbsp;</p><p>Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy, suggesting no age-related differences in the pharmacokinetics of filgrastim. The only consistently reported adverse event was musculoskeletal pain&sbquo; which is no different from the experience in the adult population.</p><p>&nbsp;</p><p>There is insufficient data to further evaluate filgrastim use in paediatric subjects.</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other special populations</u></p><p>&nbsp;</p><p><em>Geriatric use</em></p><p><em>&nbsp;</em></p><p>No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (&gt; 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients. There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.</p><p>&nbsp;</p><p><em>Paediatric SCN patients</em></p><p><em>&nbsp;</em></p><p>Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with filgrastim.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transfusion reactione</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of filgrastim overdosage have not been established. Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunostimulants, colony stimulating factors, ATC Code: L03AA02</p><p>&nbsp;</p><p>Zarzio is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.</p><p>&nbsp;</p><p>Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Zarzio containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes. In some SCN patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dose-dependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 - 2 days, and to normal levels within 1 - 7 days.</p><p>&nbsp;</p><p>Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia. Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation. The incidence of fever and documented infections were not reduced in either setting. The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.</p><p>&nbsp;</p><p>Use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into the peripheral blood. These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation. Infusion of PBPC accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.</p><p>&nbsp;</p><p>Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.</p><p>&nbsp;</p><p>One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered. In a separate retrospective international study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen. A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomized trials, eight retrospective studies and one case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Relative Risk (95% CI) of GvHD and TRM</strong></p><p><strong>Following treatment with G-CSF after bone marrow transplantation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Publication</strong></p></td><td style="vertical-align:top"><p><strong>Period of Study</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Acute Grade II - IV GvHD</strong></p></td><td style="vertical-align:top"><p><strong>Chronic GvHD</strong></p></td><td style="vertical-align:top"><p><strong>TRM</strong></p></td></tr><tr><td style="vertical-align:top"><p>Meta-Analysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>1.02</p></td><td style="vertical-align:top"><p>0.70</p></td></tr><tr><td style="vertical-align:top"><p>(2003)</p></td><td style="vertical-align:top"><p>1986 - 2001a</p></td><td style="vertical-align:top"><p>1198</p></td><td style="vertical-align:top"><p>(0.87, 1.33)</p></td><td style="vertical-align:top"><p>(0.82, 1.26)</p></td><td style="vertical-align:top"><p>(0.38, 1.31)</p></td></tr><tr><td style="vertical-align:top"><p>European</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Retrospective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.33</p></td><td style="vertical-align:top"><p>1.29</p></td><td style="vertical-align:top"><p>1.73</p></td></tr><tr><td style="vertical-align:top"><p>Study (2004)</p></td><td style="vertical-align:top"><p>1992 - 2002b</p></td><td style="vertical-align:top"><p>1789</p></td><td style="vertical-align:top"><p>(1.08, 1.64)</p></td><td style="vertical-align:top"><p>(1.02, 1.61)</p></td><td style="vertical-align:top"><p>(1.30, 2.32)</p></td></tr><tr><td style="vertical-align:top"><p>International</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Retrospective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.11</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>1.26</p></td></tr><tr><td style="vertical-align:top"><p>Study (2006)</p></td><td style="vertical-align:top"><p>1995 - 2000b</p></td><td style="vertical-align:top"><p>2110</p></td><td style="vertical-align:top"><p>(0.86, 1.42)</p></td><td style="vertical-align:top"><p>(0.86, 1.39)</p></td><td style="vertical-align:top"><p>(0.95, 1.67)</p></td></tr></tbody></table><p>&nbsp;</p><p>a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF</p><p>b Analysis includes patients receiving BM transplant during this period</p><p>&nbsp;</p><p><em>Use of filgrastim for the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation</em></p><p>In normal donors, a 1 MU/kg/day (10 &mu;g/kg/day) dose administered subcutaneously for</p><p>4 - 5 consecutive days allows a collection of &ge; 4 x 106 CD34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses.</p><p>&nbsp;</p><p>Use of filgrastim in patients, children or adults, with SCN (severe congenital, cyclic, and idiopathic neutropenia) induces a sustained increase in ANCs in peripheral blood and a reduction of infection and related events.</p><p>&nbsp;</p><p>Use of filgrastim in patients with HIV infection maintains normal neutrophil counts to allow scheduled dosing of antiviral and/or other myelosuppressive medication. There is no evidence that patients with HIV infection treated with filgrastim show an increase in HIV replication.</p><p>&nbsp;</p><p>As with other haematopoietic growth factors, G-CSF has shown <em>in vitro </em>stimulating properties on human endothelial cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Zarzio was comparable to that of the reference product after subcutaneous and intravenous administration.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>A single subcutaneous dose of 0.5 MU/kg (5 &micro;g/kg) resulted in maximum serum concentrations after a tmax of 4.5 &plusmn; 0.9 hours (mean &plusmn; SD).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution in blood is approximately 150 ml/kg. Following subcutaneous administration of recommended doses, serum concentrations were maintained above 10 ng/ml for 8 - 16 hours. There is a positive linear correlation between the dose and the serum concentration of filgrastim, whether administered intravenously or subcutaneously.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The median serum elimination half-life (t1/2) of filgrastim after single subcutaneous doses ranged from</p><p>2.7 hours (1.0 MU/kg, 10 &micro;g/kg) to 5.7 hours (0.25 MU/kg, 2.5 &micro;g/kg) and was prolonged after 7 days of dosing to 8.5 - 14 hours, respectively.</p><p>Continuous infusion with filgrastim over a period of up to 28 days, in patients recovering from autologous bone-marrow transplantation, resulted in no evidence of drug accumulation and comparable elimination half-lives.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim was studied in repeated dose toxicity studies up to 1 year in duration which revealed changes attributable to the expected pharmacological actions including increases in leukocytes, myeloid hyperplasia in bone marrow, extramedullary granulopoiesis and splenic enlargement. These changes all reversed after discontinuation of treatment.</p><p>&nbsp;</p><p>Effects of filgrastim on prenatal development have been studied in rats and rabbits. Intravenous (80 &micro;g/kg/day) administration of filgrastim to rabbits during the period of organogenesis was</p><p>&nbsp;</p><p>maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and foetal weight were observed.</p><p>&nbsp;</p><p>Based on reported data for another filgrastim product similar to the reference filgrastim product, comparable findings plus increased foetal malformations were observed at 100 &micro;g/kg/day, a maternally toxic dose which corresponded to a systemic exposure of approximately 50 &ndash; 90 times the exposures observed in patients treated with the clinical dose of 5 &micro;g/kg/day. The observed adverse effect level for embryo-foetal toxicity in this study was 10 &micro;g/kg/day, which corresponded to a systemic exposure of approximately 3 &ndash; 5 times the exposures observed in patients treated with the clinical dose.</p><p>&nbsp;</p><p>In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 &micro;g/kg/day. Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (&ge;20 &micro;g/kg/day) and slightly reduced survival rate</p><p>(100 &micro;g/kg/day).</p><p>&nbsp;</p><p>Filgrastim had no observed effect on the fertility of male or female rats.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glutamic acid</p><p>Sorbitol (E420)</p><p>Polysorbate 80</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zarzio must not be diluted with sodium chloride solution.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>Diluted filgrastim may be adsorbed to glass and plastic materials, unless it is diluted in glucose 50 mg/ml (5%) solution (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
36 months.

After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Within its shelf-life and for the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at room temperature (not above 25&deg;C) for one single period of up to</p><p>72 hours. At the end of this period, the product should not be put back in the refrigerator and should be disposed of.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Pre-filled syringe (type I glass) with injection needle (stainless steel), with or without a needle safety guard, containing 0.5 ml solution.</p><p>&nbsp;</p><p>Pack sizes of 1, 3, 5 or 10 pre-filled syringes. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution should be visually inspected prior to use. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>The inner part of the needle cap of the syringe may contain dry rubber (latex). Persons sensitive to latex should take special care with Zarzio (see section 4.4).</p><p>&nbsp;</p><p>Accidental exposure to freezing temperatures does not adversely affect the stability of filgrastim.</p><p>&nbsp;</p><p>Zarzio contains no preservative. In view of the possible risk of microbial contamination, Zarzio syringes are for single use only.</p><p>&nbsp;</p><p><u>Dilution prior to administration (optional)</u></p><p>&nbsp;</p><p>If required, Zarzio may be diluted in glucose 50 mg/ml (5%) solution.</p><p>&nbsp;</p><p>Dilution to a final concentration &lt; 0.2 MU/ml (2 &mu;g/ml) is not recommended at any time.</p><p>&nbsp;</p><p>For patients treated with filgrastim diluted to concentrations &lt; 1.5 MU/ml (15 &mu;g/ml), human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.</p><p>&nbsp;</p><p>Example: In a final volume of 20 ml, total doses of filgrastim less than 30 MU (300 &mu;g) should be given with 0.2 ml of human serum albumin 200 mg/ml (20%) solution Ph. Eur. added.</p><p>&nbsp;</p><p>When diluted in glucose 50 mg/ml (5%) solution, filgrastim is compatible with glass and a variety of plastics including polyvinylchloride, polyolefin (a copolymer of polypropylene and polyethylene) and polypropylene.</p><p>&nbsp;</p><p><u>Using the pre-filled syringe with a needle safety guard</u></p><p>&nbsp;</p><p>The needle safety guard covers the needle after injection to prevent needle stick injury. This does not affect normal operation of the syringe. Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. While maintaining pressure on the plunger, remove the syringe from the patient. The needle safety guard will cover the needle when releasing the plunger.</p><p>&nbsp;</p><p><u>Using the pre-filled syringe without a needle safety guard</u></p><p>&nbsp;</p><p>Administer the dose as per standard protocol. <u>Disposal</u></p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH Biochemiestr. 10
6250 Kundl Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MM/YYYY
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>